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SUMMARY
The study in this thesis has three main parts important to the subject of 
m odem  forensic toxicology. The first is the extraction and chromatographic 
separation of nifedipine and its metabolites from whole blood, the second is an 
evaluation of a p-cyclodextrin high performance liquid chromatography column 
and the third is the chiral analysis of temazepam enantiomers from hum an 
plasma samples.
Nifedipine is a drug used to treat angina and the analysis of this drug has 
proved difficult in the past. One of the reasons for this is that the drug is 
photolabile (decomposes in light) and where possible extraction and analysis 
must be carried out with the exclusion of light.
Several methods for the extraction of nifedipine and its metabolites were 
evaluated, these being liquid-liquid extraction, solid phase extraction and a 
combination of protein precipitation and solid phase extraction.
Liquid-liquid extraction was found to be a poor method of extraction 
because many co-eluting interferences were extracted from whole blood 
masking drug peaks. This was true of six solvents with a range of polarities.
Solid phase extraction was attem pted with the following materials : polar 
Extrelut® and non-polar C2 (ethylsilica), C8 (octylsilica), C18 (octadecylsilica), 
CH (cyclohexylsilica) and PH (phenylsilica). The Extrelut® sorbent gives poor 
extracts with many interferences from whole blood.
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Several different eluting solvent mixtures were attempted on all the non­
polar silica phases with 5 or 10% butan-l-ol in dichloromethane on C8 
(octylsilica) or C18 (octadecylsilica) sorbents giving the highest recoveries.
The percentage recovery of nifedipine from C8 and C18 is 61 and 81% 
respectively when eluted with 5% butan-l-ol in dichloromethane. The C8 
sorbent was used as the material of choice because nifedipine, nitrendipine 
(internal standard) and all three metabolites were extracted, while only 
nifedipine, nitrendipine and one metabolite were extracted on C18. A problem 
encountered with approximately one in three solid phase extraction columns 
was blockage with blood particulates, even from diluted blood.
Protein precipitation was used as an extraction step prior to solid phase 
extraction for removal of blood particulates. This was achieved by addition of 
the blood to Extrelut® or methanol. Poor recoveries (9-37% depending on 
eluant) were obtained from Extrelut® protein precipitation plus solid phase 
extraction on CH sorbent. Protein precipitation in methanol plus solid phase 
extraction on C8 sorbent gives 48% recovery for nifedipine, with all other 
compounds of interest extracted, and this was chosen as the extraction method 
of choice.
The linearity of the extraction method was proved by construction of 
calibration curves for nifedipine and nicardipine (another common anti-angina 
drug related chemically to nifedipine). The method was found to be clean, 
robust with no degradation of drug material and is used in the routine 
laboratory in the analysis of post-mortem blood samples for nifedipine and 
nicardipine.
The second part of this thesis involved evaluation of a p-cyclodextrin 
column for separation of enantiomers of four common chiral benzodiazepines 
(temazepam, oxazepam, lorazepam and lormetazepam) over several solvent 
conditions. The solvent conditions consisted of mixtures of water w ith 
methanol, ethanol, propan-l-ol and acetonitrile plus phosphate buffer w ith 
methanol and acetonitrile. Phosphate bu ffer: acetonitrile (95 :5) was also 
evaluated at different pH's (3.5,6.8,7.35) for temazepam and oxazepam.
It was found that lormetazepam separated poorly with all mobile phases, 
no separations of lormetazepam enantiomers were observed, while oxazepam 
and temazepam enantiomers separated well on most mobile phases. The most 
suitable mobile phases for oxazepam and temazepam were 5 or 10% acetonitrile 
in phosphate buffer at pH 7.35.
The third part of this thesis involved evaluation of direct chiral analysis 
for the purposes of forensic toxicology. It has been known for some time that 
enantiomers of chiral drugs may differ in pharmacokinetics and 
pharmacodynamics, and over the past 5 years regulatory bodies such as the EC 
have pu t in place draft regulations for dealing with mixtures of isomers. These 
regulations affect the pharmaceutical industry most presently, but will become 
more important to forensic toxicologists in the near future.
Two studies focused on temazepam, a chiral drug of forensic interest, and 
involved a healthy male volunteer consuming 10 or 20 milligrammes 
temazepam, with blood samples collected over 23 or 60 hours respectively.
After collection the blood was separated and plasma samples frozen. A solid 
phase extraction method with C8 sorbent was used to isolate tem azepam
enantiomers and analysis was carried out on a P-cyclodextrin high performance 
liquid chromatography column with mobile phase consisting of 5% acetonitrile 
in phosphate buffer (pH 7.35).
Both studies showed that the ratio of enantiomers was 1:1 until 12-13 
hours. The first study showed that the concentration of the first eluting 
enantiomer falls slower than the second up to 23 hours w ith the second study 
confirming this observation up to 60 hours. This suggests that the differences in 
concentration between the two temazepam enantiomers is due to stereoselective 
binding rather than stereoselective metabolism, although it is certainly possible 
that both could occur.
It can be concluded here that direct chiral separations can be applied to 
forensic toxicological analysis but requires careful planning of extraction 
strategies, because the materials used in direct chiral separations are not as 
robust as the materials used in nonchiral separations, and m any of the materials 
analysed have the potential for racemisation.
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Section 1- Introduction
Chapter 1 : General Introduction and aims
1.1 Forensic Toxicology
Toxicology is the study of poisons and the impact they have on 
biological systems. This includes physical and chemical properties of toxic 
substances, their physiological and clinical effects, and quantitative or 
qualitative methods of analysis in biological and non-biological materials.
Two basic types of exposure in toxicology are defined as acute and chronic. 
Acute exposure applies to a single episode where a harmful amount of 
substance enters the organism, and chronic exposure applies to repeated 
events in which absorption of the substance occurs. Both of these are 
important to forensic toxicology.
Since forensic means "pertaining to the courts of law " then forensic 
toxicology literally means the application of the science of toxicology within 
the legal system. In this context the word poison is used to indicate any 
chemical entity capable of having injurious effect on a living organism.
This subject is a vital component of society today because of the varied 
circumstances it benefits and clarifies. For example, a toxicological 
investigation may give insight into a death resulting from an overdose or 
from impairment of senses. This can be described as acute exposure.
Chronic exposure is also important and forensic issues resulting from 
this include drug screening for employment or road traffic incidents. 
Monitoring of individual exposure to potentially hazardous substances is 
also of interest to the forensic toxicologist, in which the subject overlaps w ith 
environmental toxicology. Examples of this include farm worker exposure to
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pesticides, inhalation of lead vapour during soldering processes by 
employees in electronics manufacturing industries or the exposure of the 
general public to anabolic agents which have been used illegally in beef 
production. The important connection between forensic and environmental 
toxicology is the use of results of the study or investigation in legal 
proceedings, either civil or criminal.
In future forensic toxicology will increasingly be involved with drug 
and substance abuse, as well as new problems. These could include female 
hormones in the environment and in food chains resulting from 
contraceptives and hum an/anim al exposure to crude oil products from the 
oil industry, for example, tanker spillages and leaks in pipelines.
1.2 Current substance abuse problems
Presently an assortment of chemical compounds are abused including 
illegal drugs, prescription-only medicines, over-the-counter medicines, 
veterinary medicines and various volatiles.
The illegal drugs include cannabis, amphetamines, opiates, cocaine 
and LSD. Cannabis has been found less addictive than other abused 
substances but at high levels of intake still causes toxicity. Amphetamine use 
seems to be on the rise in parallel with the dance and rave scene and deaths 
are on the increase. Heroin is the most widely used opiate and is a 
significant factor in many drug-related deaths in Britain today. Cocaine is 
not a serious problem in Scotland today, but its prevalence in England is 
increasing and it is anticipated that these problems will gradually spread to 
the rest of the U.K. Attributing deaths to LSD is often difficult because very 
small quantities (-60 jig) of drug are required and death is usually caused by 
an accident resulting from delusions rather than from an overdose of the 
drug.
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Prescription drugs which are abused often have 
psychopharmacological effects and include barbiturates and 
benzodiazepines. Methadone is also a commonly abused prescription drug 
even though controls are tight to make sure the drug is consumed according 
to the recommended regime. One reason for this is that often the patient will 
try and keep the methadone to sell on the street. Another problem 
encountered with prescription drugs results from the patient accidentally or 
deliberately consuming the wrong dosage. This could include almost any 
class of drug.
Veterinary medicines are also abused, mostly in rural areas and are 
usually tranquillisers or pain killers for animals. This was very rare until a 
few years ago, but there is now a steady increase of this type of abuse.
Volatiles include solvents, hydrocarbon gases and glues. Examples 
are halogenated ethane isomers, propane/butane and toluene/xylene.
Due to the wide range of substances available for abuse there is a 
constant need to develop new methods and to review old methods. Until 
recently most regulations concerning drug analysis did not require any 
stereochemical analysis, but this is gradually changing as more is learned 
about the stereochemical consequences of optically-active drugs in living 
systems.
1.3 New legislation - chiral medicinal products
An important aspect of the need for new methods could be the 
forthcoming legislation concerning chiral discrimination. A recently 
published paper [1] reviews current draft guidelines for Canada, EC, Japan 
and the United States. Most of the guidelines are similar, w ith only minor 
differences. Presently, committees for the EC and the other nations are 
trying to unify their proposals. These guidelines have come about due to the
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rapid development of stereospecific separations and also due to the need to 
separate enantiomers as more is learned about their differing biological 
activities.
The draft guidelines look at three situations which are : new single 
enantiomer, new racemate or a single enantiomer developed from a 
racemate.
The first situation treats a new single enantiomer as a new active 
substance and an application must contain all the quality, safety and efficacy 
investigations reserved for a pure substance. The only difference from a 
symmetrical molecule is that in vivo conversion and subsequent 
biotransformation should be treated as such in development and safety 
evaluation.
The next case is concerned with a new  racemate. Currently, it is 
considered as a single new active substance, although it is composed of two 
enantiomers. However, both enantiomers cannot be assumed automatically 
to show the same pharmacodynamic effects in an asymmetrical biological 
environment. The question arises as to how m uch evidence is required to be 
produced by a pharmaceutical manufacturer in order to safeguard public 
health. A balance acceptable to society must be obtained between a "no 
expense spared" approach and preserving a commercially viable workload 
for the drug licence applicant.
Two possible situations have been suggested. The first arises if the 
racemate shows rapid interconversion (racemisation), especially in vivo. The 
two enantiomers will not be considered separately under these circumstances 
and only the racemate will be investigated. This is m entioned in the EC and 
Canadian guidelines.
The other situation occurs when interconversion is slow or non­
existent, allowing both enantiomers to exert their own effects. This leads to 
the following requirements during drug evaluation :
4
Pharmacodvnamics - the main effects should be studied in animals and 
humans with the racemate and both individual er.antiomers.
Pharmacokinetics - the racemate should be studied using enantiomer-specific 
(enantiospecific) analytical methods in animals and humans, estimating 
separate exposures and deriving animal and human stereospecific 
pharmacokinetics. The interconversion should then be analysed in vivo.
Toxicology - the study should primarily focus on the racemate, but in cases 
where the toxicity is not predictable from the pharmacokinetics, the studies 
concerned should be repeated with individual enantiomers. For the 
development strategy it is important to know whether any toxicity involved 
is caused by one or both enantiomers.
Pharmacotherapy - therapeutic studies should be conducted primarily with 
the racemate and pharmacokinetic monitoring should be carried out with 
enantiospecific methods where necessary.
The last situation is a single enantiomer developed from a racemate.
It makes a difference if the change of product happens during development 
or after approval of the racemate. The first case has received emphasis in the 
FDA (Food and Drug Administration) document, and the latter in the EC 
draft guidelines. It suggests that each enantiom er in a racemic mixture 
should be monitored individually making this case differ little from the 
development of a new single enantiomer. Regulatory problems will arise 
when switching after approval of the racemate or in a late phase of 
developm ent: formally the EC requires a dossier on the enantiomer as a new
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active substance. This is considered an extreme requirement, even by the 
regulators.
The subject of chiral drug production has already been discussed at 
the national and international level and a conference for world 
harmonisation is being planned.
1.4 Aims of this work
The work in this thesis had two main aims within the context of 
method development. The first was to develop a method suitable for the 
routine analysis of the drug nifedipine in the forensic toxicology laboratory 
and the second was to evaluate the applications of chiral chromatography in 
forensic toxicological analyses.
The development of a new method for nifedipine is very important 
because of the nature of the drug, i.e. prescription-based and used to treat 
angina. This is obviously very relevant for work based in the West of 
Scotland, which has a death rate from heart disease amongst the highest in 
the world.
Chiral chromatography is a rapidly developing subject and should be 
evaluated for forensic toxicology. The recommendations in Paragraph 1.3 
above will be implemented first in the pharmaceutical industry but will have 
an impact on forensic toxicology in the future. Interpretation of results may 
change as differences in the pharmacology and toxicology of enantiomers is 
studied and methods of analysis for these will be required.
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Section II: Nifedipine
Chapter 2 : Introduction
2.1 General
Nifedipine is a commonly prescribed drug used in the management of 
angina and several other heart related illnesses. Over the past couple of 
years it has become important to develop a suitable assay, due to the drug's 
increasing importance in medico-legal cases.
2.2 Chemistry
2.2.1 Structure
Nifedipine, along with several related compounds, is based on a 
substituted dihydropyridine ring as shown below in structure 1.
H
structure 1 : substituted structure 2 : nifedipine
dihydropyridine ring
7
Often these compounds contain several common substituent features. These 
can be summarised as follows :
1. R l, R2 are ester groups
2. R3, R4 are alkyl groups
3. R5 = nitro or chlorinated benzene, but not always 
Nifedipine (structure 2) does have R1=R2 and has no chiral centre unlike 
many of the others. Some common dihydropyridine structures are 
summarised in table 1.
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2.2.2 Chemical and Physical properties
Physically nifedipine is a yellow powder w ith m.pt. 171-175°C. It is soluble 
in acetone and chloroform, partially soluble in methanol and ethanol, and 
practically insoluble in water.
The drug itself is very sensitive to light and more especially towards UV 
wavelengths. Exposure to UV light causes a loss of H2  giving dehyro- 
nifedipine (structure 3), and exposure to daylight gives dehydro- 
nitrosonifedipine (structure 4) with loss of H2 O [2]. It should be noted 
dehydronifedipine is also the first metabolite of nifedipine. This metabolite 
and all others are photostable. Also the dimer (structure 5) has been 
suggested as a possible degradation product [3].
This scheme is shown in diagram 1
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Diagram 1: Photodecomposition of nifedipine
NO,
C 02CH3
h 3c o 2c
UV light
C 0 2CH3
structure 2 : nifedipine
HqC  n  c h :
structure 3 : dehydronifedipine
daylight
N = N
Ri Ri
NO
H3C0 2C\ ^ ^ s / C° 2c h 3
HgC N CH3
structure 4 : dehydroniftrosonifedipine
structure 5 : dimer
R-j — C 0 2CH3
r2 = c h 3
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2.3 Pharmacology
Nifedipine is the prototype of dihydropyridine based compounds, 
and all are pharmacologically similar. The drug is a calcium antagonist, 
which inhibits the entry of calcium through the slow channel in the cell 
membrane of cardiac and smooth muscle cells. Calcium ions play an 
important role in the regulation of muscle contraction. At rest calcium ions 
are pum ped into the sarcoplasmic reticulum (network of membrane bound 
tubules and vesicles) so that calcium ion concentration around the muscle 
fibres is very low. Excitation of the sarcoplasmic reticulum membrane by a 
nerve impulse leads to a sudden release of calcium ions in large amounts, 
which triggers muscle contraction i.e. calcium ions are the intermediary 
between the nerve impulse and muscle contraction [4]. As well as this 
inhibition of calcium ion influx nifedipine also binds to intracellular calcium 
binding proteins.
Because nifedipine and other dihydropyridines inhibit calcium 
movement they act as arterial dilators. The effects are seen more on vascular 
smooth muscle as these are mostly dependent on calcium movement. The 
effect is seen less on cardiac muscle cells as they are dependent on sodium 
and calcium ion influx for contraction. Thus nifedipine has a selective effect 
as a dilator of arterial vessels, namely the pulmonary, coronary and 
peripheral arteries [5].
The drug is given for the treatment of angina pectoris and 
hypertension in doses of 15-80 m g /day  in divided dose form. It is usually 
administered orally but can be given intravenously if required.
Absorption has been observed over the whole length of the 
gastrointestinal tract, with 90% of the oral dose absorbed largely in the
13
proximal small intestine[6]. However the measured mean bioavailability is 
between 45 and 70%. Following administration by mouth peak blood 
concentrations are reported to occur 30-70 minutes after ingestion, w ith a 
half life of 2-5 hours [7]. The minimal plasma concentration required to 
produce cardiovascular effects is 15 |ig /L  with a typical 10 mg oral dose 
producing plasma levels around 160 M-g/L [5].
The metabolism of nifedipine appears to be hepatic oxidation to three 
metabolites which are excreted in the urine (80%) and faeces (20%). The 
pharmacological activity of nifedipine is due to the dihydropyridine ring 
structure. However the metabolites are present in the dehydrogenated form 
(i.e. based on a pyridine ring) and are thus pharmacologically inactive. A 
scheme for the metabolism is outlined in Diagram 2 and involves oxidative 
dehydrogenation to dehydronifedipine ( BAY B 4759, structure 3), followed 
by demethylation to the pyridine mono-carboxylic acid metabolite ( BAY O 
2820, structure 6), then oxidation of the 2-methyl group to the primary 
alcohol (BAY H 2228, structure 7). This metabolite undergoes pH  dependent 
cyclisation to the lactone (BAY O 4160, structure 8) [8].
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Diagram 2 : Metabolism of nifedipine
h 3c o 2 c o 2c h 3
structure 2 : nifedipine
NO/
H3C0 2<K N^ iv/ C 0 2CH
H g C r ^ N ' CH.
NO.
structure 3 : BAY B 4759 structures : BAY 0  4160
H3 C 0 2 Cv
"NO,
h 3c N‘ CH,
‘NO,
h3c o 2C \ ^ X ^ / c o 2h
h3c N ^CH2OH
structure 6 : BAY O 2820 structure 7 : BAY H 2228
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Adverse effects associated with nifedipine include dizziness, flushing, 
headache, hypotension and peripheral oedema. All of these are associated 
with the vasodilatory action. Gastro-intestinal disturbances, increased 
micturation frequency, lethargy, pain, and mental depression have also been 
noticed. Hypersensitivity reactions including rashes, fever and abnormalities 
in liver function have been reported as well as gingival hyperplasia which is 
reversible on drug withdrawal [7,9].
To date, nifedipine related deaths have not been reported in the 
literature, but several overdose cases have been published [10-16]. In these 
reports various doses have been taken (200-1000mg) with two involving 
unknown alcohol consumption [10,11]. The clinical effects are similar in all 
and include hypotension, hypoglycaemia and central nervous system 
alterations such as dizziness and weakness. The treatment involves IV 
fluids, calcium and dopamine or thiamine. Two of the cases tried gastric 
lavage with activated charcoal [11,12]. Although all patients recovered 
complications upon recovery included pulmonary oedema and 
bradyarrhythmia.
Drug-drug interactions of nifedipine with alcohol [17] and cimetidine 
[18] have been noted, with both of these inhibiting the metabolism of 
nifedipine. Ranitidine, another antihistamine similar to cimetidine, has little 
effect on nifedipine metabolism, probably due to its lower binding affinity to 
cytochrome P-450 as compared to cimetidine [18]. Nifedipine interaction 
with digoxin has been suggested, but it is thought nifedipine does not cause 
significant increases of serum digoxin, although patients on both should be 
monitored carefully [19].
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2.4 Extraction
The majority of papers published for the analysis of nifedipine from 
blood, plasma, serum or urine involve liquid-liquid extraction. A wide range 
of solvents has been used and procedures are highlighted in a recent review 
paper [20].
Approximately six methods using solid phase extraction have been 
published to date. Two of these methods involve on-line pre-column 
extraction from human plasma [21,22], another combines SPE on 
octadecylsilica (C18) and basic solvent extraction from serum and plasma 
[23] and extraction of nifedipine from serum on Bond-Elut® (BE 6001) non­
polar columns has been recorded [24]. Extractions from fetal calf serum 
using octylsilica(C8) [25] and from human plasma using octadecylsilica(C18) 
[26] have also been published.
2.5 Chromatographic methods
Several methods have been used for the chromatographic analysis of 
nifedipine and include GC and HPLC with various detectors. Approximately 
190 papers have been published involving chromatographic analysis. A 
recent review summarised 50 papers prior to 1990 [20].
Gas chromatography has been used for analysis of nifedipine and also 
dehydronifedipine, which is produced by heat or UV light degradation.
Some of the first GC methods were based on oxidation of the sample to 
dehydronifedipine [27, 28]. The procedure involves adding aqueous 
hydrochloric acid and sodium nitrite to the sample. This approach was used 
to overcome the thermal degradation of nifedipine on column. However
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these methods lack specificity since the oxidation product is also the first 
metabolite in man and this metabolite is formed quickly with a half life of 2-5 
hours [7], The methods of detection for dehydronifedipine are electron 
capture detection [27] and mass spectrometry [28]. Another mass 
spectrometry method measures plasma nifedipine with no appreciable 
oxidation [29].
Several ECD methods have been described[24,30-32] and this seems 
to be the detection method of choice for GC analysis.
HPLC is the most common analytical method in the literature for 
nifedipine assay. UV detection is by far the most common although other 
methods of detection have been tried including a carbon fibre flow-through 
amperometric detector [21].
For separation, reversed phase systems are most common, especially 
octadecylsilica [22,23,30,33,34] and, to a lesser extent, octylsilca [25,26]. 
Few normal phase separations are recorded with silica [35,36] being the 
most popular.
Most of the methods in the literature separate and detect nifedipine 
and one or two of its metabolites.
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Chapter 3 : Experimental
3.1 General Introduction
One of the aims of the work for this thesis was to find a suitable 
m ethod of extraction and chromatographic analysis for nifedipine and its 
metabolites from post-mortem whole blood samples. Several extraction 
approaches were tried including solvent extraction, solid phase extraction 
and sample pre-treatment before solid phase extraction.
A study was also completed investigating the photodegradation of 
nifedipine under two conditions : daylight and UV light.
3.2 Materials
3.2.1 Chemicals
Dichloromethane, methanol, butan-l-ol, chloroform, acetonitrile and 
propan-2-ol were of HPLC grade from BDH, Merck Ltd, Poole, UK. Hexane 
and pentane were purchased as HPLC grade from Aldrich Chemical 
Company, Gillingham, UK. Hexadecyltrimethylammonium bromide 
(cetrimide) was purchased as a normal laboratory reagent from Sigma 
Chemical Company Ltd., Poole, UK. The Bond-Elut solid phase extraction 
columns C18 (octadecyl), C8 (octyl), C2 (ethyl), CH (cyclohexyl) and PH  
(phenyl) were supplied by Varian, Harbour City, CA, USA and Extrelut® 
granules were obtained from E. Merck, Darmstadt, Germany.
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3.2.2 Drug Standards and Biological Specimens
The reference drug standards of nifedipine, nitrendipine and 
metabolites BAY-B-4759, BAY-H-2228 and BAY-O-4160 were kindly donated 
by Bayer (Germany) Ltd.
Two stock standards were prepared, the first being nifedipine and 
metabolites and the second being the internal standard nitrendipine. 
Concentrations were as follows :
Stock solution 1: nifedipine 6.1mg/L, BAY-B-4759 3.6mg/L, BAY-H- 
2228 7.1mg/L and BAY-O-4160 5.8mg/L.
Stock solution 2 : nitrendipine 7.9mg/L.
The specimens of post-mortem blood were obtained at routine 
autopsies in the Glasgow area. Blank blood was obtained from the blood 
transfusion service.
3.3 Ultraviolet Spectra
The UV spectra of nifedipine, BAY-B-4759, BAY-O-4160, BAY-H-2228 
and nitrendipine were recorded in a 50:50 water : acetonitrile solution w ith 
20mM cetrimide. This is the mobile phase used in the HPLC analysis. The 
instrument used was a Hewlett Packard 8451A diode array 
spectrophotometer.
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3.4 Chromatography
The HPLC system consisted of a solvent pump, LDC/Milton Roy 
Constametric 3000 (LDC/Milton Roy, Stone, Staffs., UK), external injection 
valve with a 20pl loop (Rheodyne model 7725), column 250x4.6mm i.d., ODS 
HL5 (Capital HPLC, Broxburn, West Lothian, UK), Waters 490-MS UV 
detector (Millipore UK Ltd /  Waters Chromatography division, Harrow, 
Middlesex) and a pen recorder (Linseis NRE-68). The mobile phase used was 
50:50 water : acetonitrile solution with 20mM cetrimide.
3.5 Photodegradation
An investigation of the photostability of nifedipine was carried out 
using a standard solution of nifedipine (5mg/L) dissolved in methanol. Two 
experimental conditions were used, namely daylight and UV light. The 
daylight exposure was carried out approximately lm  distance away from a 
basement window with full daylight, but no direct sunlight. The time of year 
was summer between l-4:30pm in the afternoon.
The UV exposure was carried out in a darkened room with no 
windows. The UV lamp used for the photodegradation experiment was a 
Spectroline® UV lamp, X= 254nm. The lamp was positioned approximately 
10cm from the sample.
The products of photolysis were analysed by HPLC using the system 
outlined in section 3.4.
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3.6 Extraction
3.6.1 Solvent Extraction
Most of the extraction methods for nifedipine in the literature are 
based on solvent extraction. Six solvents of different polarities were 
evaluated for the extraction method for whole blood. The solvents and 
polarities are summarised in Table 2 [37].
Table 2 : Polarity index of solvents
solvent polarity index 
[37]
carbon tetrachloride 1.7
diethyl ether 2.9
dichloromethane 3.4
ethyl acetate 4.3
chloroform 4.4
methanol 6.6
The procedure for solvent extraction was as follows. To separate aliquats 
were added 100 |iL of stock standard solutions and 900jliL of blank blood.
The samples were then mixed thoroughly and left to stand at room 
tem perature for 1 hour. After this each blood sample was added dropwise to 
10ml of solvent and mixed (rock and roll) for 15 minutes. Following 
centrifugation (2400rpm, 15minutes), separation and evaporation of the
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organic layer, the extract was reconstituted in mobile phase and analysed by 
HPLC.
3.6.2 Solid Phase Extraction
Direct loading of blood on to a solid phase material was attempted 
with Extrelut® and Bond-Elut C18, C8, C2, CH and PH materials.
For the Extrelut® extraction a 5ml plastic syringe barrel was filled to 
the 3ml level (approximately 0.7-0.75g) w ith extrelut® granules. The 
granules had been washed prior to use w ith dichloromethane and dried. To 
900nL aliquats of blood, 100|iL of each stock solution were added, w ith 
thorough mixing thereafter. The blood was left to stand for 1 hour. After 
this the spiked blood sample was added to the top of the column and 
allowed to absorb for 5 minutes. The elution step involved passing 10ml of 
methanol or chloroform through the cartridge followed by evaporation of 
the solvent and reconstitution in mobile phase. Analysis was carried out by 
HPLC.
For the Bond-Elut C18, C8, C2, CH and PH solid phases the following 
procedure was used -
1. Conditioning: 1 column volume methanol
1 column volume water or phosphate buffer
2. Sample application : whole blood was added and allowed to flow 
through the column very slowly, over 3-5 minutes.
3. W ashing: 1 column volume water
1 column volume hexane 
1 column volume pentane
4. E lution: 2 column volumes of eluting solvent.
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The solvents were evaporated and the extract reconstituted in mobile 
phase. Eluting solvents tried were dichloromethane, chloroform, 5% butan-1- 
ol in dichloromethane (v/v) and 10% butan-l-ol in dichloromethane (v/v).
3.6.3 Protein Precipitation and Solid Phase Extraction
Protein precipitation: 900jil of blood containing lOOpl of stock solution 
1 and lOOpl of stock solution 2 was added dropwise to 5ml of methanol and 
mixed for 15 minutes. After centrifugation (2400rpm, 15 minutes), separation 
and evaporation of the methanol, the extract was reconstituted in 1ml water 
and applied to a Bond-Elut PH solid phase extraction column.
Extrelut®: 1ml of blood spiked with standards was added to 
Extrelut® as described earlier and left for 5 minutes. Elution was tried w ith 
10 ml of chloroform, 20% methanol in chloroform and 40% methanol in 
chloroform. After the solvent had been evaporated the extract was 
reconstituted in 1ml water and applied to a Bond-Elut C8 solid phase 
extraction column.
Procedure for Bond-Elut PH and C8 extraction :
1. Conditioning -1  column volume of methanol
-1 column volume of water
2. Application of sample - the sample was allowed to flow 
through the column very slowly over 3-5 minutes
3. Rinsing - 1 column volume of water
-1  column volume of hexane
-1 column volume of pentane
4. Elution - 2 column volumes of 10% butan-l-ol in 
dichloromethane.
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The solvent was evaporated and the extract was reconstituted in mobile 
phase. Analysis was carried out by HPLC.
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Chapter 4 : Results and Discussion
4.1 Ultraviolet Spectra
The UV analysis carried out established suitable detector wavelengths 
for the assay. The data is summarised in Table 3.
Table 3 : UV Spectral data of nifedipine and its metabolites
compound wavelength (run) molar extinction coefficient
nifedipine 214 19630
236 22551
nitrendipine 208 27039
238 36074
BAY-B-4759 212 2968
268 10352
BAY-O-4160 212 14087
274 3982
BAY-H-2228 224 101748
276 55849
From the table it can be seen that the 236-238nm range has the highest molar 
extinction coefficient for nifedipine and nitrendipine.
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4.2 Chromatography
The chromatography of nifedipine was based on an HPLC method 
published in the literature, w ith several modifications. The paper suggested 
UV detection at 275nm, but after acquiring UV spectra of the compounds in 
the final mobile phase, 238nm was used instead.
The mobile phase suggested was 55:45 wateriacetonitrile and 25mM 
cetrimide with a flow rate of 0.5ml/minute. The ratio of water to acetonitrile 
was changed to 50:50, decreasing retention times, and the flow rate was 
increased to l.Oml/minute which sharpened peak shapes.
The cetrimide concentration was dropped to 20mM with no marked 
effect on the chromatography. This did however decrease the amount of 
crystallisation of the salt in the HPLC apparatus. The C18 column suggested 
in the paper was used throughout.
The capacity factors of the drugs in the final system are shown in 
Table 4.
Table 4 : Capacity factors (k1) of nifedipine and metabolites
compound capacity factor (k')
BAY-H-2228 0.69
BAY-B-4759 1.08
nifedipine 1.50
nitrendipine 2.85
BAY-O-4160 5.35
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The chromatograms for a nifedipine extract and blank blood extract 
are shown in Diagram 3 and the chromatograms of the nifedipine 
photoproducts (discussed in section 3.5) are shown in Diagram 4.
Diagram 3 : Chromatograms from nifedipine extraction
Blank blood Spiked blood
Diagram 4 : Chromatograms of photoproducts from nifedipine
nifedipine 
photoproduct from UV light
nifedipine
photoproduct from daylight
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4.3 Photodegradation
Since nifedipine is sensitive to light and might decompose during 
analysis it was important to investigate this photosensitivity. Two 
experiments were carried out, in daylight and UV light, with the results 
shown in Diagram 5.
Diagram 5 : Photosensitivity of nifedipine
cone
mg/1
7 T
daylight
uv light
4 --
3 --
2 - -
0 50 100 150 200 250
time (minutes)
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Diagram 5 shows nifedipine in daylight decomposed quickly within the first 
hour and then more slowly thereafter. In UV light nifedipine decomposed 
slowly until 90 minutes when the concentration dropped by 60% over a time 
of 30 minutes. After 120 minutes, the decomposition was slow. The diagram 
also shows that in the first 60 minutes nifedipine was more stable in UV light 
than daylight. However from 90 minutes onwards, nifedipine was less stable 
in UV light than daylight. The photolysis products were analysed by HPLC. 
The capacity factors in the system used were 1.37 and 0.73 from UV light and 
daylight respectively. However the capacity factor of the photoproduct 
(k'=1.37) from the UV experiment is not dehydronifedipine (Bay-b-4579) as 
predicted in Diagram 1.
4.4 Solvent Extraction
The three most polar solvents evaluated, ethyl acetate, chloroform and 
methanol, extracted too many co-eluting interferences from the blood. The 
three non-polar solvents, carbon tetrachloride, diethyl ether and 
dichloromethane also extracted co-eluting interferences but little evidence 
was seen of any drug material.
Therefore none of the solvents used gave acceptable results. The more 
polar solvents, in which nifedipine and its metabolites are more soluble, 
extracted so many interferences from the blood that it was impossible for 
peak identification. Since blood is such a complex mixture, it is difficult to 
use a simple solvent extraction without back extraction. No back extraction 
was tried here because the dihydropyridine ring of nifedipine is very 
sensitive to external conditions and trying a chemical step such as 
protonation of the secondary amine would cause oxidation to
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dehydronifedipine, the first metabolite. Non -polar solvents will extract 
lipids and proteins, which along with the very poor solubility of nifedipine, 
is why hydrocarbon based solvents were not attempted. Slightly more polar 
solvents such as carbon tetrachloride, diethyl ether and dichloromethane are 
also poor for nifedipine.
4.5 Solid Phase Extraction
This was evaluated extensively. The first column tested was the least 
selective non-polar material, Bond Elut C18, with phosphate buffer at pH  5.2,
7.3 and 10.3 used to condition the columns instead of water. The results are 
shown in Table 5.
Table 5 : Bond-Elut C l8 Column Elution with Dichloromethane : Effect of pH
during conditioning
compound % recovery
pH  5.2 pH  7.3 pH  10.3
Bay H 2228 / / /
Bay B 4759 66 57 49
nifedipine 37 34 46
nitrendipine 40 38 35
Bay 04160 / / /
Examination of the results shows that the pH  of the buffer used to 
condition the sorbent does not greatly affect the percentage recovery of the 
drug or its internal standard. However, only one of the metabolites was
32
eluted, prom pting an evaluation of chloroform as an eluting solvent due to 
its greater polarity. This eluant was not used subsequently due to 
interference caused by co-extracted compounds. The eluting solvent was 
changed to 5% butan-l-ol in dichloromethane with Bond Elut C18 and C8 
sorbents being used. The results are shown in Table 6.
Table 6: Elution with 5% Butan-l-ol in Dichloromethane
COMPOUND % RECOVERY
C18 C8
BAY H 2228 / 8.6
BAY B 4759 102 62
NIFEDIPINE 81 61
NITRENDIPINE 53 47
BAY 0  4160 / 30
The percentage recovery of nifedipine, nitrendipine and BAY B 4759 
from the C18 column was improved, although the C8 material did extract all 
of the substances from the blood. Further evaluation was carried out of C8 
and the more selective sorbents Bond Elut C2, CH and PH using 10% butan- 
l-ol in dichloromethane as eluant. The results are shown in Table 7.
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Table 7: Elution with 10% Butan-l-ol in Dichloromethane
COMPOUND % RECOVERY
C8 C2 CH PH
BAY H  2228 22 23 19 13
BAY B 4759 77 68 95 96
NIFEDIPINE 61 44 85 93
NITRENDIPINE 49 60 95 61
BAY 04160 25 / 16 /
An increased recovery from the C8 sorbent was observed and high 
recoveries of nifedipine, nitrendipine and the main metabolite BAY B 4759 
were obtained from the other sorbents. From these results either C8, C2, CH 
or PH sorbents combined with eluting solvent of 10 % butan-l-ol in 
dichloromethane are suitable for nifedipine extraction from whole blood. 
When the percentage of butan-l-ol was increased further (to 20% by volume) 
significant co-extracted interferences were noted. However, a major 
disadvantage of this method was that approximately 1 in 3 solid phase 
extraction columns became blocked by the blood.
The only polar sorbent tried in these studies was Extrelut® 
(diatomaceous earth). Elution with methanol was found to result in many 
interfering peaks while chloroform elution gave poor recoveries, as shown in 
Table 8.
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Table 8 : Elution with Chloroform from Extrelut®
COMPOUND % RECOVERY
BAY H 2228 /
BAY B 4759 34
NIFEDIPINE 15
NITRENDIPINE 14
BAY 04160 /
Although recoveries from direct loading of blood on non-polar 
sorbents were good in some cases, the method had to be modified to allow 
the sample to flow through the column more easily without blockage.
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4.6 Protein Precipitation and Solid Phase Extraction
To overcome the viscosity problem an initial step of either Extrelut® 
or protein precipitation was tried. With Extrelut®, 3 eluants were tried 
followed by a second stage of solid phase extraction on Bond Elut PH 
sorbent. The results are shown in Table 9.
Table 9 : Extrelut® and Bond Elut PH Solid Phase Extraction
COMPOUND % RECOVERY
% METHANOL IN 
CHLOROFORM
0 20 40
BAY H 2228 19 43 10
BAY B 4759 30 103 21
NIFEDIPINE 23 37 9
NITRENDIPINE 14 45 15
BAY O 4160 / 6 8
The results suggest that 20% methanol in chloroform is the optimum 
eluting solvent. Some decomposition of nifedipine to BAY B 4759 occurred 
here. This may have been due to the quantity of solvent required to be 
removed by evaporation (10 ml from Extrelut® + 5 ml from PH elution). 
This suggests the method is unsuitable as many methods in the literature 
caused no significant degradation.
A combination of protein precipitation in methanol followed by solid 
phase extraction using Bond-Elut C8 was tried with no degradation 
problems. The results are shown in Table 10.
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Table 10 : Protein precipitation in methanol + C8 solid phase extraction
Compound % recovery
BAY-H-2228 59
BAY-B-4759 71
Nifedipine 48
Nitrendipine 53
BAY-O-4160 25
4.7 Conclusions
This was the final method used in all subsequent nifedipine analysis. The 
method may not have matched SPE on its own in terms of percentage 
recovery, but did have the advantage of not blocking the SPE cartridges 
when whole blood is used.
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Chapter 5 : Applications
5.1 Introduction
The final recommend method was protein precipitation in methanol 
followed by SPE on Bond-Elut C8 columns. This method was used to 
construct a calibration curve for nifedipine and also to analyse several 
authentic toxicology cases.
The method was also attempted with another common 
dihydropyridine, nicardipine, with a calibration curve and a toxicology case.
5.2 Nifedipine : method validation and toxicology cases
The calibration curve for nifedipine was linear over a range of 
concentrations from 10-1000 ng /m l and the method could be extended to 
concentrations as high as lOjig/ml. Six calibration curves were carried out 
over 3 days (2 curves each day) and the data combined to give the day to day 
variation (curve as shown in Diagram 6). The equation of the line is y = 
0.024x + 0.037, the correlation coefficient was 0.999, the limit of detection is 5 
n g /m l and the limit of quantitation is 15ng/ml. Raw data used for 
construction of the curve is shown in Table 11 and the statistical data shown 
in Table 12.
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To date in the Forensic medicine and Science Department 15 requests (13 
toxicology, 2 road traffic) for nifedipine have been received. 4 of the cases 
were found to be positive by the routine technical staff. The results are 
shown in Table 11.
Table 13 : Post-mortem blood analysis positive for nifedipine a n d /o r
metabolites
case compound level (jig/ml)
1 nifedipine 8.3
BAY-H-2228 0.5
2 nifedipine 6.9
BAY-B-4759 2.7
BAY-H-2228 0.4
3 nifedipine 0.7
BAY-B-4759 3.1
BAY-H-2228 1.8
4 nifedipine 0.75
The calibration curve and the toxicology results show that the method 
for the analysis of nifedipine is robust and sensitive.
Nicardipine: calibration curve
Nicardipine is the second most commonly prescribed dihydropyridine 
after nifedipine. For this reason the method was tried with nicardipine.
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The extraction conditions and light exclusion precautions used here 
were the same as those applied in the nifedipine analysis. The percentage 
recovery of nicardipine was 59%, and using the chromatographic system in 
section the capacity factor for nicardipine is 4.93.
The calibration curve for nicardipine was linear over a range of 
concentrations from 10-500 n g /m l and, as is the case for nifedipine, can be 
extended to lOpg/ml.
The correlation coefficient was 0.987 and the calibration curve is 
shown in Diagram 7 . The limit of detection of the method is 6ng/m l and the 
limit of quantification is 18ng/ml.
Diagram 7 : calibration curve for nicardipine
2 5 “
2 0 -
ratio
1 5 -
1 0 -
5 -
0 -
100 200
conc. (ng/ml)
300 400 500
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One toxicology case was requested for nicardipine analysis. The 
technical staff, using the nifedipine analysis method, found this to be 
negative.
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Section I I I : Chiral Analysis
Chapter 6 : Introduction to Stereochemistry
6.2 General
Stereochemistry is a very important aspect of chemistry and biochemistry 
because it is concerned with the three dimensional arrangement of molecules. 
Chirality is a fundamental concept which is predominant throughout nature.
All living systems depend upon chirality and it is now being found to have an 
impact in other areas such as particle physics [38].
6.2 Historical overview
In the first half of the 19th century several French scientists studied 
diffraction, interference and polarisation of light. The study of linear 
polarisation of light and rotation of the plane of polarisation in particular 
attracted attention because of the possible relationship between these 
phenomena and the structure of matter.
Optical activity was discovered in 1815 by Jean-Baptiste Biot and in 1848 
Louis Pasteur made a set of observations on tartaric acid salts. The observations 
led him to make the following proposal: optical activity of organic solutions is 
determined by molecular asymmetry, which produces nonsuperimposable 
mirror image structures. An extension of this idea was made in 1874 when a 
theory of organic structure in three dimensions was advanced independently
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and almost simultaneously by van't Hoff and LeBet. By this time it was known 
from Kekule's work in 1858 that carbon was tetravalent. Van't Hoff and LeBet 
proposed that the four valences of the carbon atom were not planar, but 
directed in a three dimensional arrangement with Van't Hoff specifically stating 
that the shape was tetrahedral.
A compound with four different groups, which Van't Hoff defined as an 
asymmetric carbon would therefore be capable of existing in two distinctly 
different nonsuperposable forms. The asymmetric carbon atom was therefore 
the cause of molecular asymmetry and thus optical activity [39].
6.3 Basic terms and concepts
6.3.1 Symmetry [40]
Symmetry or asymmetry are properties found in all molecules. At a 
mathematical level, symmetry elements and operations have been devised to 
display the geometrical properties of molecules. The elements and operations in 
symmetry are shown in Table 14.
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Table 14 : Elements and operations of symmetry
symmetry element symbol symmetry operations
proper (simple) axis of rotation Cn rotations
planes of symmetry a reflections
centre of symmetry (of inversion) i inversion
rotation - reflection axes (mirror 
axes, improper axes, alternating 
axes)
Sn rotation-reflections
To illustrate these elements the benzene molecule will be used as an example. 
Structures 9 and 10 in Diagram 8 show the symmetry elements of benzene.
Diagram 8 : symmetry elements of benzene
structure 9 : benzene - symmetry axes and centre of symmetry
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structure 10 : benzene - planes of symmetry
A molecule is said to have a symmetry axis Cn if a rotation of 360°/n 
around this axis yields an arrangement indistinguishable from the original, i.e. 
benzene has and C2  axes.
When a plane divides a molecule into 2 symmetrical halves, it is called a 
plane of symmetry. Benzene has 2 vertical planes (ov) and 1 horizontal plane 
(oft) of symmetry.
A centre of sym m etry, (i), exists in a molecule where every atom has a 
symmetrical counterpart with respect to the centre of symmetry, and this is true 
of benzene.
In general molecules may possess none, one, or a num ber of elements of 
symmetry. Although the number of molecules in existence is huge, the possible 
combinations of symmetry operations are few and the combinations are called 
point groups.
The principal point groups for chiral molecules are shown in Table 15.
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Table 15 : Point groups for chiral molecules
point group elements
C l no symmetry elements 
(asymmetric)
Q i Cn (n>l) dissymmetric 
(axial symmetry)
Dn Cn, nDn (dissymmetric) 
(dihedral symmetry)
6.3.2 Chirality
Chirality is defined as the property displayed by any object which is not 
superposable (superimposable) on its mirror image. Therefore a molecule 
cannot be chiral if it contains a plane of symmetry, such molecules being termed 
achiral. The word chiral comes from the Greek %eipoa (chiros) which means 
hand. This seems a sensible description for the property, since each hand is a 
mirror image of the other and they are non superposable.
Several structural features cause chirality including a chiral centre, alternating 
chiral axis, chiral plane and helical structures.
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6.3.2.1 Chiral centre
A chiral centre is described as a tetrahedral distribution of 4 different 
groups around an atom. Most commonly the atom is carbon and several 
examples are shown below (structures 11-13).
H
J "1 M ''C l  4 CH, 
B r
H
4 sHn C *  C l  
J B r
mirror plane 
structure 11 : 1-bromo-1-chloroethane
HO
NH
OH
NH
structure 12 : propranolol
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I H ^
N  CH3 CH.
•3
N
structure 13 : nicotine
Other elements in group IV such as silicon and tin can also have chiral centres 
due to their tetravalency.
Atoms need not belong to group IV to possess a chiral centre, provided a stable 
tetrahedral arrangement can be reached. Examples are nitrogen (structures 14 
and 15), phosphorus (structure 16) and sulphur (structure 17).
R l
+
R 3""’F \
* R lR2
structure 14: ammonium 
ion
structure 15 : trisubstituted ammonia
R2 O
R2
structure 16 : phosphinate
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6.3.2.2 Alternating chiral axis [41]
The alternating chiral axis really describes the chirality of 4 groups 
arranged out of plane in pairs about an axis. This is illustrated by the elongated 
tetrahedron in structure 18.
R4r :
structure 18 : elongated tetrahedron
When no distinction exists between the 4 groups, R1-R4, the tetrahedron 
has a 4 fold axis of symmetry. Differences of any kind between the groups cause 
chirality. It should be noted that fewer differences in groups are required 
compared with a chiral centre, e.g. the pairs must be different, R1^R2, R3?tR4 
but this is the only constraint.
Many examples of this exist including allenes (structure 19), 
alkylidenecycloalkanes (structure 20) and biaryls such as biphenyl in structure 
21.
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R l
R l/// R2
R4R3
structure 19 : allene
R 3 ^  R4
structure 20 : alkylidenecycloalkane
R l
R3
R2 
■ R4
structure 21 : biphenyl
6.3.2.3 Chiral plane [42]
A plane of chirality occurs in molecules where the molecular plane is 
removed by the presence of a bridge. Examples of this include trans- 
cycloalkenes such as trans cyclooctene (structure 22) or substituted 
paracyclophanes (structure 23).
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structure 2 2 : transcycloctene structure 2 3 : substituted 
paracyclophane
6.3.2.4 Helical structures
Helices are chiral objects found in the everyday world (e.g. helical shells, 
left and right handed screws) as well as in chemistry. Examples are helicenes 
such as hexahelicene (structure 24) and biological macromolecules eg. DNA.
structure 2 4 : hexahelicene
6.3.3 Spectroscopic measurement of optical activity
Light [43], when considered as a w ave , vibrates at right angles to the 
direction of travel. There are an infinite number of planes passing through the 
line of propagation, with the light vibrating in all of these planes. This 
phenomena is represented in Diagram 9.
Diagram 9 : Natural light
direction of movement
6.3.3.1 Circularly polarised light
Circularly polarised light is light in which the electric field vector rotates 
around the direction of movement, either clockwise or anticlockwise. This 
effectively produces light which moves in a circular helical manner and a 
representation of this is shown in Diagram 10.
Diagram 10 : Circularly polarised light
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6.33.2 Plane polarised light
In plane polarised light the electric field vector remains in a plane 
containing the propagation axis as shown in Diagram 11.
Diagram 11: Plane polarised light
Plane polarised light can be considered as the resultant of the composition of 
two contra-rotating (circularly polarised) light beams of equal amplitude.
6.3.3.3 Elliptic light
Elliptic light is the composition of two unequal contra-rotating circularly 
polarised light beams giving light in which the electric vector describes an 
ellipse when observed in a plane perpendicular to the beam. The elliptic light is 
regarded as left or right circularly polarised depending upon which light (left or 
right) has the greatest amplitude.
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6.3.3 A  Interaction of plane polarised light w ith chiral molecules [44]
Linearly polarised light is thought of as being two beams of circularly 
polarised light which propagate together in phase but in opposite rotational 
senses. When the linearly polarised light passes through an achiral medium, 
each of the two circularly polarised light beams pass through the material at the 
same velocity and thus have the same refractive indices. However, w hen the 
linearly polarised light passes through a chiral medium, phase differentiation 
occurs because the two circularly polarised light beams will have different 
refractive indices. This is because the chiral medium will absorb one of the 
components of circularly polarised light more than the other, and thus produce 
elliptic light.
It is the elliptic light which is measured by optical rotatory dispersion (ORD) 
and circular dichroism (CD).
6.3.3.5 Optical rotatory dispersion and circular dichroism
ORD and CD are both spectroscopic techniques which measure the 
interaction of UV light with a chiral medium over a full UV spectrum. In ORD 
the extent to which the beam of linearly polarised light is rotated (angular 
rotation) is the only parameter measured. However in CD the angular rotation 
is measured along with the different absorbances produced by the two circular 
components (of plane polarised light) as they travel through the chiral media.
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6.3.3.6 Polarimetry and nuclear magnetic resonance (nmr)
The other two main spectroscopic techniques that can be used for analysis 
of chiral media are polarimetry and nmr. Polarimetry is very similar to ORD 
except that ORD measures the full UV spectrum , whereas polarimetry only 
measures selected wavelengths. One of the older naming systems used for 
optically active compounds was derived from the use of polarimeters. If the 
rotation of the light is clockwise, then the substance is dextrorotary, and if the 
rotation is anticlockwise, the substance is levorotarory. The symbols (*) or d are 
given for dextrorotary and (-) or 1 for levorotarory. The actual value of the (+) or 
(-) shift can be measured in degrees using a polarimeter.
NMR is a useful technique for analysis but one drawback is the requirement for 
a relatively large amount of sample with a minimum mass of a few 
milligrammes. Depending upon the geometry of the sample, a chiral additive 
may be required for nmr. The theory behind this technique can be found in 
most advanced chemistry textbooks, and a good review paper on its application 
to chiral phenomena was published in 1991 [45].
6.3.4 Labelling optically active compounds [46]
One method of naming optically active compounds has been mentioned 
above in section 6.3.3.6.
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6.3.4.1 R/S notation
Another method used is the Cahn-Ingold-Prelog R /S  rules. These rules 
are designed so that a particular stereochemistry of a molecule can be 
mentioned without drawing the structure.
Two steps are involved in this process :
Step 1 : Following a set of sequence rules a priority is assigned to the four 
atoms or groups attached to the chiral centre.
The sequence rules are :
Sequence rule 1: if the four atoms attached to the chiral centre are all 
different, priority depends on atomic number, with the atom of higher atomic 
number getting higher priority 
e.g. Cl > C > H
Sequence rule 2 : if the priority cannot be decided by rule 1 then go to the 
next atom in the group (and so on, working outwards from the chiral centre).
An example of this is shown in structure 25.
H
c h 3 — c h 2— c h 2 — c — OH
c h 3
structure 25: pentan-2-ol 
Priority here is :
OH > propyl > methyl > H
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Sequence rule 3 : when a multiple bond is present, both atoms are also 
multiplied, as shown in structures 26 a,b.
H
— i = o
structure 26a : aldehyde structure 26b : consequence of rule 3
Now that the sequence has been established, step 2 involves visualisation.
Step 2 : the molecule is orientated so that the ligand of lowest priority is 
directed away from the viewer. If we view pentan-2-ol (structure 25) in this 
manner the arrangement below is observed.
(C H J
OH
structure 27 : (S) - pentan-2-ol
When proceeding from the ligand of highest priority to the lowest, a 
clockwise rotation is specified as R and anticlockwise as S.
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It should be noted that the R /S and (±) notations have no association. 
This is because (±) unlike R /S  is a physical property of a substance. If both 
labels are known, then they should be used e.g. R-(-)- etc.
6.3.4.2 Helices
Helices have been classified as M or P where M denotes a left handed 
helix and P denotes a right handed helix.
6.3.5 Enantiomers and racemates
One of the requirements for a chiral molecule is that it cannot be 
superimposed on its mirror image. These mirror images are known as 
enantiomers, which have similar chemical and physical properties except for 
optical activity. A 50:50 mixture of enantiomers is known as a racemate (or a 
racemic mixture).
Often the products of a reaction, or a mixture of enantiomers, are not 
racemic and the ratio is defined as the enantiomeric excess i.e. % major - % 
minor.
For example, a mixture with R=major, [R] donates concentration of R
[R] - [S]enantiomeric _ 1 1 1 J x -jqo
excess +
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6.3.6 Diastereoisomers
So far the discussion has been based on molecules with 1 chiral centre. A 
molecule w ith 2 or more chiral centres is known as a diastereoisomer 
(sometimes shortened to diastereomer), has 2n separate forms and 2n“l  pairs of 
enantiomers, where n=number of chiral centres.
For example the compound 2-bromo-butan-3-ol (structure 28) has 2 chiral 
centres and thus 4 enantiomers (structures 28a,b,c,d).
OH
B r
structure 28 : 2-bromo-butan-3-ol
CH, CH, CH, CH,
H-
H-
•OH
■Br
HO-
B r -
HO-
H -
■H
■Br
H-
B r-
■OH
■H
CH, CH, CH, CH,
structure 28a,b : (± ) erythro form structure 28c,d : ( ± ) threo form
The projection above is known as a Fischer projection and its relationship 
to other spatial representations is shown in Diagram 12.
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Diagram 12 : Spatial representations
Fischer eclipsed staggered Newman projection
\  /
sawhorse
The naming system in 28a,b,c,d is based on the sugar erythrose (structure 
29) and threose (structure 30) and the standard nomenclature for compounds 
with 2 chiral centres and different substituents at each centre. In the Fischer 
projection, when the highest priority groups are on the same side, the 
enantiomers are the erythro form, and on the opposite sides for the threo form.
CHO
■OH
■OH
c h 2o h
CHO
HO'
HO-
c h 2o h
CHO
H-
HO-
■OH
•H
c h 2o h
CHO
HO' 
H —
■H
■OH
c h 2o h
structure 29 : (±) erythrose structure 30 : (±) threose
The 2n rule is broken if each chiral centre has identical substituents. In 
this case there are 3 forms : (+), (-) and meso. (+) and (-) are related as 
enantiomers and to the meso form as diastereoisomers. This is illustrated by 
tartaric acid (structures 31 a,b,c).
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c o 2h c o 2h c o 2h
H OH HO H H OH
HO H H OH H OH
c o 2h c o 2h c o 2h
structure 31a,b : (±)tartaric acid structure 31c : meso tartaric acid
6.3.7 Prochirality [47]
This describes non-chiral molecules which have the potential to become 
chiral by a chemical reaction. There are 2 types of prochirality: prochiral centre 
and prochiral faces.
6.3.7.1 Prochiral centre
A prochiral centre usually involves 4 groups around a tetrahedral carbon, 
as shown in structure 32.
Here R1*R2, but X=X'. Replacement of X' with another group ,Y, gives the (R)- 
enantiomer (structure 33a) and replacement of X gives the (S)-enantiomer 
(structure 33b). X' is known as the pro-R group and X is known as pro-S. X and 
X' are collectively known as enantiotopic groups if R1 and R2 are non chiral. If
R 1
X
structure 32 : prochiral centre
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diastereoisomers are formed (i.e. R1 and /o r R2 are chiral) they are known as
diastereotopic groups.
R1 R1
R 2 l ' '  Y R2li''// X1
X Y
structure 33a : R-enantiomer strucutre 33b : S-enantiomer
6.3.7.2 Prochiral faces
Similarly, non chiral molecules containing carbonyl or alkene groups can 
be described. If a general carbonyl group is taken in a plane (structure 34) there 
are 2 possible faces available for attack in a reaction. When the molecule is 
viewed from above and the R /S sequence rules are used the Newman projection 
shown in structure 35 is obtained.
Z
H
^ __
R
^  si
structure 34 structure 35
In this case the top face is a clockwise rotation of priority and is labelled re. An 
anticlockwise rotation is labelled si, as may be viewed from the bottom in this 
case. These faces are known as enantiotopic if R is achiral and diastereotopic 
faces if R is chiral.
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6.3.8 Pharmacological definitions
Two description of enantiomers which often appears in the literature are 
eutomer and distomer. The eutomer describes the enantiomer most potent for 
the desired action and the enantiomer without such action is called the 
distomer.
The eudistic ratio is the ratio of the activities of eutomer and distomer and the 
eudistic proportion is the proportion of the concentrations of eutomer and 
distomer in the biological matrix (i.e. blood, plasma etc.).
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Chapter 7 : Stereochemistry and Pharmacology
7.1 Introduction
Most naturally occuring medicinal agents exist in their optically active 
or single isomer form. Since these compounds are produced in nature, they 
exist in one isomeric form, due to the inherent chirality of the natural world. 
For example proteins are made up of L-amino acids, while carbohydrates are 
of the D-configuration [48].
However, many synthetic chemicals are produced as the optically 
inactive racemate. A recent survey [49] shows that in 1991 a greater 
percentage of synthetic drugs were being sold as single enantiomers as 
compared to 1982. This trend is mainly due to the improvement of chiral 
separation techniques and tighter regulatory controls.
Since human and animal systems are chiral environments, and many 
drugs have stereochemical properties, it is important to review 
stereochemical effects in pharmacology in some detail. The two main aspects 
are the stereochemical nature of drugs and the effects of stereoselectivity in 
drug pharmacology.
7.2 Stereochemical nature of drugs [50]
The stereochemical nature of drugs can result in their subdivision into 
two broad catagories with respect to pharmacology. In the first of these the 
pharmacological activity is due to one enantiomer only, while in the second, 
the activity differs both qualitatively and quantitavely in each enantiomer.
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7.2.1 Pharmacological activity is, or appears to be, due to 1 enantiomer
Three possible situations can result in pharmacological activity being 
associated with one enantiomer.
The first of these is where all activity does in fact reside in one 
enantiomer. An example of this is the antihypertensive agent a-methyl dopa 
(structure 36) [51].
The second case is when both enantiomers have similar activity and 
potency. This is a very rare situation since receptors and enzymes react to 
stereochemical differences. An example of this is propafenone (structure 37), 
where the 2 enantiomers have equal activity with regard to antiarrhythmic 
activity [52].
HO
'3 COOH
structure 36 : a-methyl dopa
O
H
structure 37: propafenone
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The third situation is when the enantiomers have similar activities, but 
potencies differ. This situation does not present a therapeutic problem and 
examples include warfarin (structure 38) and verapamil (structure 39). The 
potency of S-(-)-warfarin, in vivo, is from 2  to 5-fold greater than R-(+)- 
warfarin [53]. Verapamil, a calcium channel blocker used as an antianginal 
agent and for the treatment of supraventricular tachyarrhythymias, shows 
different potencies between the two enantiomers. Both R(+)- and S(-)- 
verapamil equally increase cardiac blood flow through coronary 
vasodilation, but the (R) isomer is eight- to ten-fold less potent a 
cardiodepressant as compared with the S(-) isomer [54].
structure 38: warfarin
CHji o c h 3
c h 3 o c h 3
structure 39: verapamil
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7.2.2 Pharmacological activity differs qualitatively and quantitatively in each 
enantiomer
Drugs of this type can again be divided into 3 different catagories.
The first of these is when single enantiomers are marketed because of 
the effects of the other enantiomer. Examples of this are L-dopa and a- 
dextropropoxyphene (structure 40).
HO
W \
COOH
structure 40 : dextropropoxyphene structure 41 : dopa
For dopa (structure 41) it was noticed that many of the serious side effects, 
such as granulocytopenia, were due to the D-isomer [55]. D-propoxyphene 
has analgesic properties, whereas its optical isomer L-propoxyphene has 
antitussive properties, but no analgesic properties [56]. The company Lilly 
gave them trade names which are also mirror images of each other, Darvon® 
and Novrad®.
The second situation arises when a racemic drug is developed despite 
unwanted activity in one isomer. Examples of this include ketamine 
(structure 42) and cyclophosphamide (structure 43).
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structure 42: ketamine structure 43 : cyclophosphamide
All of these are marketed as racemic mixtures with the enantiomers of each 
drug varying greatly in their pharmacological and toxicological profiles. 
Ketamine is a commonly used anesthetic and analgesic drug. Post anasthesia 
reactions to ketamine include hallucinations and agitation. When the 
potency ratio was investigated, the S-(+)-enantiomer had 3-4 times the 
potency of the R-(-)-enantiomer, with the side effects associated with the 
R-(-)- enantiomer [57]. The drug cyclophoshphamide (structure 43) owes its 
asymmetry to a chiral phosphorus atom and its (-)-enantiomer is twice as 
effective an antitumour agent but no more toxic than the (+)-enantiomer [58]. 
It can be seen in the two examples above that it would have been 
advantageous to market single enantiomers.
The third case of differing pharmacology is when the racemic product 
may have therapeutic advantages. A good example of this is labetalol 
(structure 44) for which the racemic product is useful for a percentage of the 
patient population.
OH
NH
HO
structure 44: labetalol
Labetalol is diastereomeric and is marketed as an equal mixture of all 4 
stereoisomers. The pharmacological effects of each isomer [59] are 
summarised in Table 16.
Table 16 : Pharmacological effects of labetalol stereoisomers
isomer effect
R,R non specific Pi -, p2 - blocker
S,R a-] -blocker
S,S inactive
R,R inactive
The combined product is useful because some patients require P-blockage 
(R,R) and also vasodilation (S,R). On the other hand the two inactive isomers 
might advantageously be excluded from the product. Because of this and the 
fact that some patients do not require vasodilation, the single R,R isomer is 
being developed (dilevalol).
7.3 Stereochemistry of drug pharmacology
Once the stereopharmacological nature of the drug is known, the 
disposition and metabolism of the drug must be considered.
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7.3.1 Drug disposition, binding and clearance [60]
Many of the events involved in drug disposition do not involve
stereochemical interactions. However exceptions to this do occur if the drug 
molecule interacts specifically with biological macromolecules.
7.3.1.1 Drug absorption
Most drugs are absorbed from the intestine, airways or skin by 
passive diffusion of unionised drug across lipid membranes. The diffusion is 
controlled by two properties which do not show stereoselectivity, namely the 
degree of ionisation of the drug (dependent on pKa) and the solubility of the 
unionised form. Two drugs which do show stereoselectivity in absorption 
are methotrexate (structure 45) [61] and dopa (structure 41) [62], with the In­
forms of each being actively absorbed and D-forms crossing the intestinal 
wall passively. Methotrexate is used for the treatment of solid tumours.
H2N
O
C 02H
c o 2h
structure 45: methotrexate
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7.3.1.2 Drug distribution
In the drug distribution phase the majority of drugs cross the blood- 
brain barrier or penetrate organs by passive diffusion. However, one 
example of stereochemically selective distribution involves the R-isomers of
2 -arylpropionic acids (e.g. ibuprofen) which are selectively incorporated into 
adipose tissue [63].
7.3.1.3 Plasma protein binding [64]
Unlike absorption and distribution, protein binding often depends 
upon stereochemical conformations, and most drugs undergo some degree of 
binding to plasma proteins. Two plasma proteins are responsible for the 
majority of drug binding : serum albumin which accounts for the bulk of 
drug binding, especially acidic solutes, and o^-acid glycoprotein (AGP) to 
which weakly basic drugs bind preferentially. Although isomers may 
differentially bind to particular binding sites on plasma proteins, large 
conformational flexibility of the proteins may allow binding to other sites 
[65]. This area is still undergoing vigorous investigation.
7.3.1.4 Renal excretion
The elimination of drug substances an d /o r metabolites from the 
kidney is a major elimination route. Glomerular filtration itself is not 
stereoselective and only unbound drug in plasma water is filtered. Therefore 
other factors such as stereoselective protein binding will result in isomers 
exhibiting differences in renal clearance. However drugs which are cleared
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by active secretion in the renal tubules may show stereoselective elimination. 
An example of this is quinidine (structure 46) which has fourfold higher 
renal clearance than its diastereoisomer quinine (structure 47) [6 6 ].
HO HO
•ni
structure 46 : quinidine structure 47 : quinine
7.3.2 Metabolism [67]
As mentioned earlier, absorption, distribution and excretion are 
generally passive processes which do not discriminate between enantiomers. 
However protein binding and enzymatic metabolism can show a high degree 
of stereoselectivity. This comes from the fact that interaction of the 
enantiomers of a chiral drug molecule with a chiral macromolecule, e.g. an 
enzyme, will give a pair of diastereoisomeric complexes. Similarly, the 
binding of a prochiral substrate to an enzyme, will orientate two enatiotopic 
groups differently, making them diastereotopic.
The metabolic transformations of compounds m ay be categorised in 
terms of five stereochemical courses. Their transformations are prochiral to 
chiral, chiral to chiral, chiral to diastereoisomeric, chiral to non-chiral and 
metabolic chiral inversion.
74
7.3.2.1 Prochiral to chiral transformations
This is a metabolic transformation which could occur at enantiotopic 
groups, either at a prochiral centre, or at a remote site from the chiral centre. 
An example of this is the transformation of ethylbenzene (structure 48) to 1- 
phenylethanol (structures 49 a,b) [6 8 ] as outlined in Diagram 13.
Diagram 13 : Transformation of ethyl benzene to 1-phenvlethanol
H H
structure 48 : ethylbenzene structures 49 a,b : 1-phenylethanol
A general situation which can occur is the reduction non-symmetric ketones 
giving a chiral centre in the secondary alcohol product. A num ber of 
prochiral ketones have been examined as substrates giving the (S)-alcohols in 
80% or greater [6 8 ]. These reactions are potentially difficult to predict or 
control because the binding orientation of the substrate towards the enzyme 
active site is not open to control. Therefore the chirality of the product is 
solely a function of the biological system responsible for the metabolism and 
cannot be influenced by the drug substrate administered, since 
stereochemical differences do not exist until metabolism has occurred.
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7.3.2.2 Chiral to chiral transformations
Many examples exist of chiral compounds whose individual 
enantiomers are transformed at different rates an d /o r by different routes to 
metabolites with the original stereochemistry. An example of this is the 
stereoselective metabolism of warfarin enantiomers. The metabolism of 
warfarin administered as separate enantiomers in humans [69] is 
summarised in Diagram 14.
Diagram 14 : Metabolism of warfarin 
R-(+)-warfarin S-(-)-warfarin
▼ v
6-hydroxywarfarin 7-hydroxywarfarin
* v
(R,S)-warfarin alcohol (S,S)-warfarin alcohol
7.3.2.3 Chiral to diastereoisomeric metabolites
Diastereoisomeric metabolite formation is very common in drugs 
already containing a chiral centre. The way this can happen is by 
transformation of prochiral groups or by formation by reaction with a 
conjugate molecule from the body. An example of this could be one of the 
steps in the complex metabolism of warfarin . Two of the principal routes of 
metabolism are the aromatic hydroxylation of the 6- and 7-position of the 
coumarin ring and ketone reduction in the side chain [70]. This ketone
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reduction results in the formation of diastereoisomers as outlined in 
Diagram 14.
Conjugation reactions in the body are very common and the 
endogenous conjugating agents are often called endocons. Two groups of 
endocons exist, achiral and chiral. Examples of achiral endocons are methyl 
and acetyl groups, sulphate and the amino acids glycine (structure 50) and 
taurine (structure 51). Common chiral endocons are glucuronic acid 
(structure 52), glucose (structure 53), glutathione (structure 54) and 
glutamine (structure 55). Conjugation of enantiomeric drugs with these 
chiral endocons will give enantiomers, and since the endocons are of fixed 
conformation, two will be possible. Many examples of this exist including 3- 
hydroxylated benzodiazepines (oxazepam, temazepam, lorazepam and 
lormetazepam) with glucuronic acid [71].
structure 50 : glycine structure 51 : taurine
C 0oH
OH
.OH
HO
H OH
OH
.OH
HO OH
structure 52 : glucuronic acid structure 53 : a-D-glucose
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O CH2SH h 
structure 54: glutathione
NH
structure 55: glutamine
7.3.2.4 Chiral to non-chiral transformations
Examples of this transformation are rare, although it may occur when 
secondary alcohols yield ketones. A good example is of the deamination of 
amphetamine to yield phenylacetone [72].
7.3.2.5 Metabolic chiral inversion
Some drugs undergo quite extensive racemisation in vivo and data on 
the biological properties of a single enantiomer should be interpreted 
carefully. Many of the 2-arylpropionic acids (profens) undergo this 
conversion. These non steroidal anti-inflammatory drugs (NSAID's) have a 
chiral centre a  to a carbonyl group, and the biological activity resides mainly 
in the (S)-enantiomer. The (R)-enantiomers are often weakly active or 
inactive. In vitro the metabolic inversion of the (R)-enantiomer to the (S)- 
enantiomer occurs [73, 74]. The initial observations were made with 
ibuprofen but since then the metabolic transformation has been observed for 
many other 2 -aryl propionic acid drugs.
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Chapter 8 : Temazepam and benzodiazepines
8.1 General
Temazepam is a member of the benzodiazepine class of drugs. Over 
3000 benzodiazepine type drugs have been synthesised. About 35 are in 
clinical use throughout the world, with approximately 14 recommended for 
use in the UK. Temazepam in particular has been prescribed for sedation and 
insomnia relief, but more recently has been abused by drug users.
8.2 Chemistry
8.2.1 Planar structure
The term benzodiazepine refers to a molecule which contains a 
benzene ring fused to a seven membered diazepine ring. However all the 
important benzodiazepines contain a 5-aryl substituent and a 1,4-diazepine 
ring, and the term has come to mean 5-ary 1-1,4-benzodiazepines [75].
The basic structure [76] and that of temazepam are illustrated below
CH
OH
Cl
R2
R7
R4
R2'
structure 56 : general 5-aryl- structure 57 : temazepam
1,4-benzodiazepine
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Most commonly in the 5-aryl-l,4-benzodiazepine structure, R7=C1, F or NO2 , 
R2 =carbonyl, R2 '=H or halide, R i=H or alkyl.
Other common benzodiazepines are summarised in Table 17.
Table 17: common benzodiazepines
benzodiazepine Ri r2 r 3 R7 r 2
bromazepam* H =0 H Br H
chlordiazepoxide n h c h 3 H Cl H
clobazam c h 3 =0 H Cl H
clonazepam H =0 H n o 2 Cl
clorazepate H =0 coo- Cl H
demoxepam H =0 H Cl H
diazepam c h 3 =0 H Cl H
flunitrazepam c h 3 =0 H N02 F
flurazepam c h 2c h 2
N(C2Hs)2
=0 H Cl F
halazepam CH2CF3 =0 H Cl H
lormetazepam c h 3 =0 OH Cl Cl
lorazepam H =0 OH Cl Cl
nitrazepam H =0 H n o 2 H
nordazepam H =0 H Cl H
oxazepam H =0 OH Cl H
prazepam - < =0 H Cl H
quazepam CH2CF3 =s H Cl F
temazepam c h 3 =0 OH Cl H
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Modifications of this basic structure have yielded compounds with similar 
activities, including 1,5-benzodiazepines (e.g.clobazam, structure 58) and 
those in which the benzene ring has been replaced with heteroaromatic rings 
such as thieno (e.g. brotazolam, structure 59).
CH
Cl
structure 58: clobazam
Br
structure 59: brotazolam
8 2 2  Three-Dimensional structure and conformations of 1,4-benzodiazepines 
Diazepam
Diazepam is considered to be achiral because it has no chiral centres. 
However it does have a chiral plane [77] and the 2 conformations are shown 
be low :
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Cl
Ph
structure 60a : M - diazepam
Ph
Cl
structure 60b : P - diazepam
It can be seen that the 7-membered heterocyclic ring forms a boat shape 
with the N1 methyl and C5 phenyl groups pointing away from the C3 point. 
However, the barrier for inversion of the heterocyclic ring is not high enough 
to prevent ring inversion, and the 2  forms are in thermal equilibrium at room 
temperature.
3-substituted 1,4-benzodiazepines
Monosubstitution of the C3 position stabilises one of the 
conformations, depending on the absolute conformation of position C3. For 
the (R)-enantiomer the P conformation is more stable, whereas for the (S)- 
enantiomer the M conformation is more stable. This is because the larger
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substituent at C3 cannot point into the ring for steric reasons. The crystal 
structure for temazepam [78,79] agrees with this and suggests this 
conformational argument is true for 3-hydroxyl derivatives. X-ray crystal 
analysis has also been carried out on (R)- and (S)- l,3-dimethyl-5-(2- 
fluorophenyl)-7-nitro-l,3-dihydro-2H-l,4-benzodiazepin-2-one [80]. The 
molecule is shown below ( no stereochemical features shown) in structure 61.
From the crystal data the conformations preferred for each enantiomer are 
shown be low :
CH.
structure 61 : 1,3-dimethyl-5-(2-fluorophenyl)-7-nitro- 
1,3-dihydro-2H-1,4-benzodiazepin-2-one
structure 6 2 a : R-conformer structure 6 2 b : S-conformer
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These two conformations can be generalised for the (S)- and (R)- enantiomers 
of 3-substituted 1,4 benzodiazepine.
8.2.4 Circular dichroism (CD) ofl,4-benzodiazepin-2-ones
Several investigations have taken place on the properties of 1,4- 
benzodiazepin-2-ones [81,82,83,84,85]. The studies which investigated 3- 
substituted-analogues did not include either oxazepam or free (non- 
complexed) temazepam, but looked at various 3-alkyl substituents [81,83], 3- 
ester substituents and lormetazepam. Other investigations obtained data on 
diazepam [85], and complexes of several l,4-benzodiazepin-2-ones (including 
temazepam) w ith (3-cyclodextrin [84].
It was noted in all of these studies involving free or non-complexed chiral 1,4- 
benzodiazepin-2-ones that there was a positive CD below 300 nm and a 
negative CD between 300-350 nm for the (S)-enantiomers, with the opposite 
being true of the (R)-enantiomers.
8.2.5 Chemical and Physical properties
Temazepam is a white crystalline powder with m.p. 156-159°C. It is 
practically insoluble in water, but soluble 1 in 10 in both ethanol and 
chloroform. Its pKa is 1.6.
8.3 Pharmacology
8.3.1 Effects
The effects of the benzodiazepines all result from actions of these drugs 
on the central nervous system (CNS). These include sedation, hypnosis,
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decreased anxiety, muscle relaxation, anterograde amnesia and 
anticonvulsant activity. Only two effects on peripheral tissues have been 
noted, these being coronary vasodilation, seen after intravenous 
administration of therapeutic doses of certain benzodiazepines, and 
neuromuscular blockage, seen only in very high doses.
8.3.2 Benzodiazepine binding sites and GABA receptors
The main mechanism through which benzodiazepines are believed to 
exert all their actions, including anxiolytic, sedative, anticonvulsant and 
muscle relaxation, is by enhancing the inhibitory activity of GABA (gamma 
aminobutyric acid) at GABAa inhibitory synapses.
GABA is the principal inhibitory neurotransmitter in the CNS, and 
there are at least two types of GABA receptor in the brain, namely GABAa 
and GABAb. The GABAa receptor controls chloride ions at the anion channel 
and GABAb receptor controls potassium ions at the cation channel. 
Benzodiazepines exert their action by binding to GABAa causing an increase 
in neuronal inhibition. Since the GABAg binding site is not influenced by 
benzodiazepines it will not be discussed.
GABAa consists of several subunits named a, (3, y, 8, with 
benzodiazepines binding strongly to y and GABA to the (3 subunit. The 
important receptors and binding sites are summarised below in Diagram 15 
[86].
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Diagram 15 : binding sites at GABA^ receptors
benzodiazepine GABA 
binding site receptor
p-carboline 
binding site
cr
y-subunit p-subunit
ion channel
barbituate 
binding site
Other classes which interact with benzodiazepine receptors include inverse 
agonists and specific antagonists. Inverse agonists such as betacarbolines have 
opposite effects on the receptors resulting in reduced affinity of the GABA 
receptor to cause anxiologenic and preconvulsant effects. Specific antagonists 
such as flumazenil bind to the benzodiazepine receptor and block both types 
of modulatory agonists [87, 88].
8.3.3 Classification
The benzodiazepines may be classed as long-, intermediate- or short- 
acting compounds [89]. The long acting drugs are either Nl-desalkyl 
derivatives, e.g. delorazepam and nordazepam, or are oxidised in the liver to 
these compounds, e g. chlordiazepoxide, diazepam, flurazepam and 
prazepam. These long-acting benzodiazepines are characterised by formation 
of desalkyl (nor) derivatives. Further biotransformation of the nor derivatives 
is slower than the initial desmethylation of the parent compounds and
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accumulation can occur after a few days treatment. The rate limiting step of 
their metabolism (with the exception of 1,5- derivatives) is C3 hydroxylation 
to oxazepam or lorazepam (2 ' halogenated derivative).
The 7-nitro derivatives such as clonazepam, flunitrazepam and 
nitrazepam are metabolised by nitroreduction with no important known 
active metabolites and are classed as intermediate acting.
The short acting benzodiazepines include C3-hydroxylated compounds 
such as lorazepam, lormetazepam, oxazepam and temazepam which undergo 
rapid conjugation w ith glucuronic acid to water-soluble inactive metabolites 
that are excreted in the urine [90]. Temazepam is also converted to oxazepam 
in small amounts [91].
The half-lives of several of these compounds are shown in Table 18 
along with their therapeutic doses.
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Table 18 : Half-lives and therapeutic doses of commonly prescribed
benzodiazepines
benzodiazepine use half-life (hrs) 
(plasma)
daily dose 
(mg)
flurazepam hypnotic 2-3 * 15-30
loprazolam hypnotic 4-11 (mean 7) 1-2
lormetazepam hypnotic 10 0.5-1
nitrazepam hypnotic 18-38 (mean 28) 5-10
temazepam hypnotic 3-38 (mean 10) 10-30
flunitrazepam hypnotic 10-70 (mean 25) 0.5-1
lorazepam anxiolytic 9-24 (mean 14) 1-4
chlordiazepoxide anxiolytic 5-30 (mean 15) 40-100
diazepam anxiolytic 20-100 (mean 48) 6-30
clobazam anxiolytic 10-58 (mean 25) 20-60
bromazepam anxiolytic 8-19 (mean 12) 3-18
oxazepam anxiolytic 4-25 (mean 8 ) 180
clorazepate K anxiolytic 2 * 7.5-22.5
alprazolam anxiolytic 6-20  (mean 12) 0.25-3
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8.4 Stereoselective chiral binding
Several studies have been completed which suggest differential 
binding of the enantiomers of chiral 1,4-benzodiazepines to hum an plasma 
proteins and animal brain tissue.
8.4.1 Human serum albumin
One study [92] involved the use of circular dichroism (CD) to 
investigate the binding of four 1,4-benzodiazepines to hum an serum albumin 
(HSA). The main structure and ring substitutions are shown below in 
structure 63 and the table below :
R
Cl
structure 63 : 5-aryl-1,4-benzodiazepin-2-one
R R 1 name
H H nordazepam
c h 3 H diazepam
H c h 3 3-methyl-nordazepam
H 0C0(CH 2)2C02H
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Three other studies [93,94,95] have used a chiral stationary phase, based on 
HSA bound to silica, for investigation of structural requirements and binding 
sites. Two of these studies [93,94] suggest that there is more than one binding 
site on HSA for benzodiazepines. This conclusion does not agree with the CD 
study [92]. However the studies [93,94,95] should be treated more carefully 
as it is difficult to say how well a chromatographic system will mimic HSA in 
the hum an body.
8.4.2 Bovine brain tissues
Another study [96] focuses on the binding of three chiral 1,4- 
benzodiazepines (3-substituted nordazepams) to bovine cerebral cortex. The 
structures of these are shown below in structure 64a :
R = CH3, OCOCH3 or 
OCOC(CH3)3
structure 6 4 a : 5-aryl-1,4-benzodiazepin-2-one
It was found in this study that the (S)-enantiomer was up to one hundred fold 
more potent in displacing ^H-flunitrazepam from cerebral receptors than the 
(R)-enantiomer.
The results have been confirmed by a similar study on bovine brain 
membranes [82]. Once again, tritiated flunitrazepam was displaced, the (S)-
Cl
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enantiomers showing greater affinity for the brain membranes. The 
compounds were 3-substituted nordazepam derivatives and are summarised 
be low :
Cl
structure 64b : 5-aryl-1,4-benzodiazepin-2-one
R X
OCOMe H
OCOMe Cl
OCOBu* H
0C 0(CH 2)2C02- H
Me H
8.4.3 Rat brain tissues
Several studies have been carried out on rat brain tissues. One of these 
[97] suggests that the (+)-enantiomer of oxazepam sodium hemisuccinate 
displaces ^H-diazepam binding 10X as effectively as the (-)-enantiomer in rat 
cortex tissue.
Another study focused on ^ H - d ia z e p a m  displacement from rat cerebral 
cortex [98] and noted differential enantiomer binding.
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8.5 Medical problems with benzodiazepines
8.5.1 Dependence
Benzodiazepines, although very useful, can be addictive. Dependence 
is frequently a problem when prescriptions of duration 3-4 weeks and longer 
are given out and is thought to occur in about one third of all patients 
receiving benzodiazepines. Research has shown that approximately 35% of 
patients prescribed benzodiazepines for longer than 4 weeks are likely to 
develop a significant degree of dependence [99]. The meaning of dependence 
here is that a person is unable to stop the drug after the appropriate period 
w ithout withdrawal problems. Major symptoms of withdrawal occur in less 
than 2 0 % of patients and include acute brain syndrome, delirium, confusion 
and psychosis. The majority of patients develop more minor conditions such 
as increased anxiety, insomnia, irritability, dysphoria, headache, nausea, 
tremors and difficulty in concentration an d /o r sensory disturbances [100]. It 
is quite ironic that some of these conditions may have been the reason for 
administration in the first place.
8.5.2 Toxicity
The benzodiazepines are thought to be less toxic than many other 
drugs in overdose. However a recent study [101] has shown that certain 
benzodiazepines have a higher fatal toxicity index (measured in deaths per 
million prescriptions) than some of the tricyclic antidepressants. 
Flunitrazepam, temazepam and diazepam have the highest indices. Another 
study [102] shows there is a large difference in sedation levels obtained after
92
overdose for several benzodiazepines. However temazepam is one of the 
most likely to cause death, possibly also due to the habit of injecting this drug 
[101]. It may also be taken orally in conjuction with alcohol, especially in 
suicide cases.
8.5.3 Injection of temazepam
Temazepam has a high fatality index which was thought to stem in 
part from its widespread popularity with drug abusers. However injecting 
temazepam tends to be habitual in young people and only 45% of temazepam 
deaths in England and Wales occurred in young people, the same as triazolam 
[101]. Triazolam is the other widely prescribed short acting hypnotic, which 
is not commonly employed by drug users [103]. Several studies have been 
published suggesting a growing number of drug users injecting temazepam 
only [103,104,105], or as a cocktail with other drug substances such as 
buprenorphine [106,107,108]. One of the problems with injection of 
temazepam was the use of gel filled capsules as a source of the drug. When 
the contents of these capsules are injected intraarterially instead of 
intravenously, complications such as limb ischaemia can occur [109].
8.6 Extraction
Many methods have been published in the literature concerning 
benzodiazepine extraction from biological fluids. Liquid-liquid extraction is 
commonly used, but problems here include possible hydrolysis of the ring 
system from acids/bases used in the back extraction. A recent review [110] 
focused on all extraction techniques as well as biopharmacological data and 
high performamce liquid chromatography. Another recent paper [111]
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reviewed solid phase extraction of 1,4-benzodiazepines from biological fluids. 
For urinary benzodiazepine conjugates, enzymatic and acid hydrolysis has 
also been reported [11 2 ],
8.7 Chrom atography
8.7.1 Achiral
Nonchiral chromatographic assays for benzodiazepines are numerous 
in the literature. Methods include HPLC and GC with a review from 1990 
[113] summarising many chromatographic methods.
HPLC is a commonly used technique for benzodiazepine analysis with 
non polar phases such as octadecyl (C18) being popular. An example of this 
is the gradient analysis of 15 benzodiazepines and selected metabolites from 
post-mortem blood [114].
GC has been used with various detectors including flame ionisation 
detection [115], nitrogen phosphorus detection [116,117] and dual analysis 
with electron capture and nitrogen-phosphorus detection [118]. Gas 
chromatography with mass spectral detection is commonly employed 
especially for urinary metabolites [119,120], selected ion monitoring for 
"natural" benzodiazepines in hum an serum [121] and negative chemical 
ionisation in urine samples [12 2 ].
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8.7.2 Chiral
Chromatographic separation of chiral benzodiazepines has been 
extensively carried out by high performace liquid chromatography. Four 
phases have been investigated, namely Pirkle type phases and those based on 
ovomucoid protein, hum an serum albumin and p-cyclodextrin.
Pirkle phases have been used to separate lorazepam and several esters 
(found on the 3-position) [123]. In this study 6 closely related Pirkle phases 
were used. Another study [124] used the Pirkle phase (S)-N-(3,5- 
dinitrobenzoyl)phenylalanine as a chiral selector for the separation of 
oxazepam, temazepam, lorazepam and lormetazepam. All four drugs had a 
resolution, R>1 on one of the three mobile phases evaluated. The two studies 
involve a chromatographic analysis of pure standards and not of biological 
samples.
The protein phase, ovomucoid bound to silica, was used for the 
separation of the chiral metabolites of medazepam [125]. Medazepam is not 
chiral itself, but the 3-hydroxy metabolites have a chiral centre. Again this 
application did not involve biological samples.
Human serum albumin, as well as being a transport protein, is used as 
a selector for chiral stationary phases. Three studies [93,94,95] have used this 
stationary phase to examine binding sites and structural requirements for 
various benzodiazepines.
Several studies have involved p-cyclodextrin bound to silica as a chiral 
selector for benzodiazepines. Two of these [126,127] analysed separation 
factors for several racemic benzodiazepines. Another two studies [128,129] 
involved the analysis of benzodiazepine glucuronides in hum an urine 
samples. In both cases some separation was obtained on octadecyl (C18)
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bonded silica with full separation of diastereoisomers being obtained on p- 
cyclodextrin.
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Chapter 9 : Chromatographic enantiomeric separation
9.1 Introduction
Over the past 25-30 years there has been an increase in the popularity 
of chromatography for separating enantiomers. These methods require 
formation of a diastereoisomeric complex, with the main two m ethods being 
direct and indirect resolution. Direct resolution involves injecting the 
enantiomers into the chromatographic system without chemical alteration, 
which has a stationary or mobile phase with some kind of chiral recognition 
capability. Indirect resolution involves reaction of the enantiomer(s) with a 
stereochemically pure reagent to form diastereoisomeric complexes, prior to 
achiral chromatography.
9.2 Direct resolution
Several advantages of this method exist over indirect resolution. The 
main one is that no sample pre-derivatisation is required, leading to direct 
on-column separation. Several chiral phases have been developed and 
applied to techniques such as HPLC and GC.
9.2.1 High performance liquid chromatography
All chiral HPLC stationary phases are based on a chiral selector 
molecule bonded to the silica. There are 5 basic types of selector, based on 
the recognition and mechanisms of formation and these are summarised as 
follows [130]
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Type I : solute/stationary phase complexes are formed by attractive 
interactions, hydrogen bonding, n-K interactions, dipole stacking etc.;
Type I I : the primary mechanism for the diastereoisomeric complex 
formation is attractive interaction, but inclusion can also be important;
Type m  : the solute enters a cavity in the stationary phase, forming an 
inclusion complex;
Type IV : the solute is part of a diastereoisomeric metal complex;
Type V : the stationary phase is a protein and the complexes are formed 
though a combination of hydrophobic and polar interactions;
New stationary phases : antibiotics
9.2.1.1 Type I stationary phases : Pirkle type phases
The type I phases may also be known as synthetic multiple-interaction 
phases, but are more commonly referred to as Pirkle phases. This is after 
W.H. Pirkle who has done much work in this area from its beginnings in 
1979 to the present day. A review has recently been published covering the 
history of the Pirkle laboratory and many of the phases designed [131].
The Pirkle stationary phases depend on the three-point rule [132], 
which states chiral recognition requires a minimum of three simultaneous 
interactions between the stationary phase and at least one of the
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enantiomers. At least one of the interactions must be stereochemically 
dependent. A pictorial representation is shown below in Diagram 16.
Diagram 16 : three point rule
C',
B enantiomer 1
B
C '*
- B1 A' enantiomer 2
D'
silica
support
From Diagram 16 it can be seen enantiomer 1 interacts at three sites : 
A-A', B-B', C-C1, whereas mirror image 2 does not interact at A-A'. Therefore 
differences in binding energy are possible and each enantiomer will spend a 
different amount of time on the phase. The stationary phases are designed so 
that each interaction is different.
Commonly, the 3 functional groups are :
1 .7t-acidic or 7t-basic aromatic groups, i.e. capable of donor-acceptor 
interactions;
2 . polar hydrogen bond an d /o r dipole stacking sites ;
3. bulky non-polar groups, providing steric repulsion, van der waals
interactions, an d /o r conformational control.
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An example of a commercially available phase is (R)-phenylglycine-3,5- 
dinitrobenzoyl, shown in the following structure :
In the above structure, the three interactions for this particular phase 
are shown, and many other phases are similar with minor structural 
differences. For example the n-n interactions could be increased by changing 
the benzene ring to a napthalene ring, or an electron donor group could 
replace the dinitrobenzoyl group.
Many classes of compound have been separated on Pirkle phases with 
several drug classes of interest being antihypertensives, antianginals and 
antiinflammatories [133].
H-bonding
NHCO CH NHCO
k- k interactions electron acceptor 
ie. charge transfer
structure 65 : (R)-phenylglycine-3,5-dinitrobenzoyl
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9 2 .1 2  Type II stationary phases : cellulose [134]
Cellulose is a good choice of material for chiral stationary phases due 
to its inherent optical activity and abundance in the biosphere. It is a highly 
ordered crystalline polymer consisting of D-(+)-glucose units joined by a-1,4 
linkages as shown in structure 66
n
structure 66: cellulose
X-ray analysis has shown that these chains lie side by side in bundles, 
held together by hydrogen bonds. These bundles become twisted together 
forming rope-like helical structures. Since cellulose consists of chiral 
subunits (D-(+)-glucose), chiral recognition may occur either through 
attractive interactions between the solute and D-(+)-glucose or by inclusion 
of the solute into the cavities/channels between the chains.
However it was found that natural cellulose did not have enough 
mechanical strength for HPLC, which prom pted manufacture of several 
derivatives. These are shown below in Diagram 17.
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Diagram 17 : derivatives of cellulose
OR
RO
O-
basic cellulose structure
some possible structures for R
O
CH,
acetate benzoate
■CH, / /  W
methyl ether
CH
ii
CH
cinnamate
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o o
< <
NH NHA
H3 C CH'3
phenyl carbamate 3,5-dimethyl-
phenylcarbamate
One important practical consideration for these stationary phases is 
that chlorinated solvents will remove the derivatised cellulose support. This 
is also true of acetone, DMSO and methyl ethyl ketone. However, solvents 
such as hexane, propan-2 -ol, ethanol, methanol or water can be used safely.
The celluloses have been used for separation of many drug 
compounds including mephobarbital and mephenytoin on 
cellulose tris(4-methylbenzbate) [135] and bevantolol on 
cellulose tris(3,5-dimethylphenylcarbamate) [136].
9.2.1.3 Type 111 stationary phases : inclusion complexes
These phases require an inclusion complex to form between the solute 
and stationary phase. Three types of molecule are bound to silica, namely 
cyclodextrins, polymethacrylates and crown ethers.
9.2.1.3.1 Cyclodextrin bonded phases [137]
Cyclodextrin molecules are cyclic oligosaccharides comprising six to 
twelve glucose molecules bonded in a-1,4 linkages. The molecules are 
toroidally shaped and the most commonly used in chromatography are a, [3
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and 7-cyclodextrin, containing 6 , 7, 8  glucose units respectively, p- 
cyclodextrin is shown in structure 67.
OH
OH
HOOH
HOO OH
HO
OHOH
HO
HO
OH
HOQ
OH
HO
OH
-<J OH
OH OH
HO
OH
structure 67: p-cyclodextrin
One or two of the primary hydroxyl groups are used to link the cyclodextrin 
to the support, with the secondary hydroxyl groups lining the m outh of the 
cavity. The mouth of the cyclodextrin is therefore more hydrophilic w ith the 
lining being relatively hydrophobic due to the glycosidic oxygen bridges.
The mechanism of separation relies on the fact that part of the solute 
molecule should fit into the cyclodextrin cavity (inclusion) so that the centre 
of asymmetry of the analyte is associated with the polar hydroxyl groups at 
the edge of the cavity. Therefore the asymmetric centre may be up to 4 
bonds away from the aromatic moiety. The size of the cyclodextrin cavity is 
very important in determining the type of compound separated. As a 
general rule substituted phenyl, naphthyl and biphenyl rings can be
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separated on P-cyclodextrin while smaller molecules may separate on a- 
cyclodextrin. Larger molecules such as 4 or 5 ring steroids can be separated 
on 7-cyclodextrin.
Many derivatives of cyclodextrins have been produced with p- 
cyclodextrin being the most commonly altered. The molecules are bonded to 
the secondary hydroxyl and examples include (R)- and (S)- 
naphthylethylcarbamate [138], carboxymethyl- and carboxyethyl-[139], all 
bonded to p-cyclodextrin.
Commercially available derivatives [140] include acetyl (a, p and 7- 
cyclodextrin), (R)- and (S)- napthyl ethyl carbamate (p-cyclodextrin) and 3,5- 
dimethyl phenyl carbamate (P-cyclodextrin).
A number of drugs have been separated on p-cyclodextrin including 
ibuprofen [141], terfenadine [142] and several amphetamines [143].
9.2.1.3.2 Polymethacrylate phases
These phases have been developed from polymerisation reactions 
forming optically active synthetic networks or helices. The polymerisation 
m ust be completed carefully with the use of a chiral reagent or chiral 
catalyst. If a chiral monomer is used, then crosslinking polymerisation 
occurs which results in a chiral polymer network. Examples of this are 
polyacrylamides and polymethylacrylamides of which the general structure 
is shown in structure 6 8 .
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structure 68: polyacrylamide
If a chiral catalyst is used on an achiral monomer then isotactic 
(stereoregular) single handed helical structures are produced. An example of 
the basic structure is shown below in structure 69.
Ar
i
Ar—C— Ar 
i /o—c
C H ,— C
2 I
R
structure 69:
9.2.1.3.3 Chiral crown ethers-
Crown ethers are synthetic macrocyclic polyethers that can form 
selective complexes with various cations. An 16-crown-6-ether is shown in 
structure 70, where the 16 indicates the total number of atoms in the 
polyether ring and 6 the number of oxygen atoms.
structure 70 :1 6-crown-6-ether
In structure and R2  are the chiral elements of the crown ether. R^ 
and R2  are chosen and added to hinder rotation of the crown ether about its 
axis of disymmetry.
The 16-crown-6-ether is particularly useful in forming stable 
complexes with potassium and ammonium ions because the cavity size and 
electrostatic properties of the oxygen atoms suit these molecules. Thus a 
structural requirement in the analyte is a primary amine moiety, such as in 
amino acids and small peptides.
9.2.1.4 Type IV - Ligand exchange chromatography [144,145]
Chiral ligand exchange chromatography works on a principle 
involving metal atoms for diastereoisomeric formation. The separation 
occurs on a square planar transition metal atom such as copper(II) or 
nickel(II) with four possible binding sites for ligands. Two of the binding 
sites on the atom are taken by one enantiomer of a chiral bidentate amino 
acid such as L-proline (structure 71) or L-alanine (structure 72).
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C 0 2H NH
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structure 71 : proline structure 72: alanine
This complex takes on a "chiral" character and enantiomeric mixtures 
of suitable compounds, such as amino acids or other bidentate molecules, are 
separated due to interaction with the complex.
In most cases a nonpolar stationary phase such as C18 is used with a 
mobile phase containing the chiral selector (amino acid and copper(II) salt). 
However several stationary phases have been manufactured. These have an 
amino acid such as proline or valine bonded directly to the silica and the 
copper(II) salt is added to the mobile phase.
9.2.1.5 Type V : Protein based stationary phases [146]
Proteins are high molecular weight biological polymers and are 
composed of L-amino acids. One function of proteins in biological systems is 
to bind xenobiotic compounds. Because of this and the fact they are 
inherently chiral, proteins have been bonded to silica as chiral stationary 
phases.
Proteins which have been bound include ai-acid glycoprotein (AGP), 
albumin (SA) as either hum an serum albumin (HSA) or bovine serum 
albumin (BSA) and the enzyme ovomucoid (OVM) obtained from chicken 
egg whites.
The most common conditions for type V phases are similar to a 
biological environment i.e. aqueous mobile phase containing buffer at pH  7.
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Under these conditions many interactions occur including hydrogen 
bonding, hydrophobic and electrostatic interactions.
Many chiral separations of drugs have been established on protein 
phases including warfarin on OVM [147], p-blockers on AGP [148] and 
omeprazole (gastric acid inhibitor) on AGP, OVM and BSA [149].
9.2.1.6 New stationary phases : antibiotics [150]
A new class of chiral selectors has been developed, namely 
macrocyclic antibiotics bonded to silica. The two commercially available at 
present are vancomycin (structure 73) and teicoplanin (structure 74) [151].
Both of these could be described as multimodal phases because the 
complex chiral environments they contain. For example they can mimic 
Pirkle phases in certain respects due to the abundance of amine, amide, 
carboxylic acid and substituted benzyl groups. Also, these phases contain 
cavities with possibilities for inclusion complexation.
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9.2.2 Gas chromatography [152]
Direct separations by gas chromatography have not made the same 
advances as in liquid chromatography. One of the main reasons is the 
difficulty in preparing a stationary phase which will withstand the high 
temperatures often encountered in gas chromatography.
The three main types of stationary phase used are hydrogen bonding 
phases, chiral metal coordination compounds and cyclodextrin type phases.
9.2.2.1 Hydrogen bonding stationary -phases
These phases require the formation of hydrogen bonds between the 
analyte and phase. The analytes often require derivatisation to increase 
volatility an d /o r introduce suitable groups for hydrogen bonding. Reagents 
used for this include isocyanates and phosgene.
Several commercial phases are based on the following structure :
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CH, CH,
Si O-
(CH2)m 
HgG— CH
■Si O-
CH,
0= CONHCH(CH3)3
! IH 
CH(CH3)3
where m=1-3
structure 75: Chirasil-Val
9.2.22 Metal coordination compounds
Another type of stationary phase is that resulting from the complex 
resulting from divalent transition metal ions and terpene ketones.
The most successful is nickel(II)-[3-(heptafluorobutanoyl)-(lR)- 
camphonate]. This was bonded to dimethylsiloxane with the resulting 
structure shown below.
• 0-
CH,
I J 
■Si-
CH,
I c
•S i-
CH2
CH,
CH
Ni/2
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Chiral recognition takes place when the analyte donates electrons to 
the nickel atom forming a diastereoisomer. Compounds which have been 
separated include cyclic ethers, esters, acetals, aldehydes, ketones and 
alcohols from classes such as pheromones and essential oils. The major 
disadvantage is the low temperature range of operation which is 25-100°C. 
The 2 in structure 75 means that another heptafluorobutanoyl-(lR)- 
camphonate molecule is bound to the nickel atom.
9.2.2.3 Cyclodextrin type phases [153]
Cyclodextrin based polysiloxane derivatives have been the most 
successful stationary phases for GC having operating temperatures from 25- 
250°C. Above this temperature the phase is still mechanically stable, but the 
cyclodextrin has lost its enantioselectivity. It should be noted that 
differences between phases from different manufacturers may result in an 
upper limit between 200-250°C.
Native p- and 7-cyclodextrin are available as stationary phases, but the 
vast majority are per-O-alkyl derivatives such as heptakis (2,3,6-tri-O- 
methyl)-p-cyclodextrin. These structures are very similar to the cyclodextrin 
structure shown in section 9.2.1.3.1 except alkyl groups usually replace the 
alcoholic hydrogen atoms of the glucose molecules.
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Chapter 10: Experimental
10.1 Materials
10.1.1 Chemicals
Methanol, ethanol, propan-l-ol, propan-2-ol, acetonitrile were HPLC 
grade from BDH, Merck Ltd, Poole, UK. Hexane was purchased as HPLC 
grade from Aldrich Chemical Company, Gillingham, UK.
Potassium dihydrogen orthophosphate, sodium dihydrogen orthophosphate, 
disodium hydrogen orthophosphate and orthophosphoric acid were GPR™ 
grade, all being obtained from BDH.
The Bond-Elute solid phase extraction columns C8 (octylsilica) were supplied 
by Varian, Harbour City, CA, USA.
10.1.2 Drug standards and biological specimens
The reference drug standards of benzodiazepines (temazepam, oxazepam, 
lormetazepam, lorazepam and diazepam) were obtained from Sigma-Aldrich 
Chemical Company Ltd, Poole, UK.
10.2 Chromatography
The HPLC system consisted of a solvent pump, LKB 2150 (LKB- 
Produkter AB, Box 305, S-161 26 Bromma, Sweden), external injection valve 
with a 20|il loop, column 250 x 4.0 mm i.d., LiChroCART® 250-4 ChiraDex®
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P-cyclodextrin (E. Merck, Darmstadt, Germany), Waters 490-MS UV detector 
(Millipore UK Ltd /W aters Chromatography division, Harrow, Middlesex) 
and a pen recorder (Linseis NRE-6 8 ). The reversed phase column used was a 
250 x 4.6 mm i.d. ODS HL5 (capital HPLC, Broxburn, West Lothian, UK).
10.3 Extraction
10.3.1 Extrelut® extraction
The Extrelut® extraction method for benzodiazepines used routinely 
in the Department of Forensic Medicine and Science was used. The method 
involved the addition of 0.25 ml of 5% ammonia solution and 1 ml phosphate 
buffer (0.05M, pH  7.4) to 1 ml blood. The blood was then mixed for several 
minutes. While mixing occurred 0.25 ml 5% ammonia solution is added to 
the columns containing Extrelut® (approximately 8 grammes per column). 
The mixture was then added to the columns and left for 5 minutes for 
absorption. The drugs were then eluted with the addition of 8  ml diethyl 
ether. The ether was then evaporated and the sample was reconstituted w ith 
mobile phase prior to chromatography.
10.3.2 Solid phase extraction on octylsilica (C8)
The solid phase extraction method was designed such that no steps 
involved acid or base, because of possible racemisation of temazepam under 
these conditions.
The sample pre-treatment and C8 methods were as follows :
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pre-treatm ent: add 1ml (or 2ml) 0.05 M phosphate buffer (pH 6 .8 ) to 
lm l (or 2ml) blood or serum and mix well.
SPE 1. conditioning: 1 column volume of methanol
1 column volume of 0.05 M phosphate buffer
(pH 6 .8 )
2. sample : add slowly over 2-3 minutes
3. w a sh : 2 column volumes of water
1 column volume of hexane
4. elution : 1 column volume of 80% methanol in water
The samples were then evaporated to dryness and reconstituted in 
mobile phase.
This solid phase extraction method was used on plasma samples for 
chiral and non-chiral analysis.
10.3.3 Liquid - liquid extraction for semi-preparative samples
Individual enantiomers were collected as fractions following HPLC 
using the mobile phase 10% acetonitrile in water. The excess acetonitrile was 
evaporated and a liquid - liquid extraction carried out. Several solvents were 
evaluated for this purpose, including diethyl ether, ethyl acetate, 
dichloromethane and chloroform. Ether was selected. Following the 
extraction, the ether was evaporated and the two enantiomers were 
dissolved in methanol, which was then evaporated. This extra step was to 
remove any traces of diethyl ether from the enantiomers.
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Prior to this extraction of the enantiomers, several solvents were 
evaluated in the liquid-liquid extraction. The solvents were ethyl acetate, 
diethyl ether, dichloromethane and chloroform.
10.4 Circular dichroism
Circular dichroism spectra of temazepam enantiomers were recorded 
on a Jasco J-600 Spectropolarimeter with a 0.1 cm cell.
10.5 Oral administration of temazepam and collection of the samples
Two separate experiments were carried out on a healthy male 
volunteer. In the first study one lOmg tablet of temazepam was 
administered (swallowed with a mouthful of water) with collection times up 
to 24 hours. In the second study, two lOmg tablets were administered with 
collection times up to 60 hours.
The sample collection and storage were as follows : 10ml blood was 
collected in a heparinised vial and mixed gently. Serum was separated 
immediately by centrifugation at 3000 rpm for 10 minutes, with the 
separated serum frozen until analysis.
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Chapter 11 : Results and discussion I
11.1 Introduction
High performance liquid chromatographic chiral separations using 
cyclodextrin bonded silica can be carried out in reversed, normal or polar 
organic mobile phase conditions. Because the P-cyclodextrin stationary 
phase contains a nonpolar inclusion cavity and polar hydroxyl groups at the 
mouth of the cavity, either of these can be supressed to give reversed phase 
or polar organic conditions.
When cyclodextrin stationary phases are used with aqueous mobile 
phases, the basic retention mechanism is inclusion complexation. This 
mechanism involves the attraction of the apolar molecule or molecular 
segment to the apolar cavity. The cavity of the cyclodextrin becomes very 
selective when an aromatic group is present as there is electron sharing 
between the aromatic methylene groups and the glucoside oxygens. It is 
therefore essential that if a chiral separation is attempted in reversed phase 
mode then the analyte must have at least one aromatic ring.
In the normal phase mode for cyclodextrins the mobile phase is very 
similar in theory to that used with achiral chromatographic columns. In this 
particular case inclusion complexation and polar interactions such as 
hydrogen bonding occur between the stationary phase and analyte.
The polar organic mode derives its name from having polar mobile 
phase constituents such as anhydrous triethylamine and glacial acetic acid 
and does not include any water. Usually a mixture of solvents is used 
containing small amounts of both triethylamine and glacial acetic acid. In
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the polar organic phase, inclusion complexation is supressed and analytes 
interact with the secondary hydroxyl groups across the larger opening of the 
cyclodextrin. Since three points are required for chiral recognition, the 
solvent pool in the cyclodextrin cavity is seen as one. Therefore at least two 
functional groups capable of surface interaction must be present in the 
analyte. This mobile phase should be a good alternative to reversed phase 
systems because different requirements on the analyte are demanded, and 
separations may occur where inclusion was not possible.
In this study the reversed phase mode was evaluated for separation of 1,4- 
benzodiazepines. The chiral resolution factors were investigated for 
oxazepam, temazepam, lormetazepam and lorazepam, with particular 
reference to temazepam.
11.2 Chromatography
11.2.1 M obile phase effects
Several mobile phases were tested and resolution factors obtained. 
These included water : alcohol mixtures, water : acetonitrile mixtures, buffer : 
alcohol mixtures and buffer : acetonitrile mixtures.
11.2.1.1 Water: alcohol/acetonitrile mixtures
In reversed phase systems using cyclodextrins it is known that the 
type and ratio of organic modifier to aqueous part in the mobile phase affects 
stereoselectivity. Several solvents were mixed in varying degrees with 
water, the solvents being methanol, ethanol, propan-l-ol and acetonitrile.
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Methanol w a te r: mixtures
For m ethanol: water mixtures 5,10 ,20 ,and 40% methanol mixtures 
were investigated. The results are shown in Diagram 18.
Diagram 18 : Enantiomeric resolution of chiral benzodiazepines versus
percentage methanol
resolution
10 T
temazepam
oxazepam
4 ”
lormetazepam
2 -
5 10 2015
% methanol
From the results it can be seen that 10% methanol gave the best 
separation of enantiomers for temazepam and oxazepam. Lormetazepam 
showed no real change when the percentage of methanol was changed from
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5 to 10% methanol, and above this no resolution of enantiomers was noted 
with one peak only being observed. With 40% methanol all drugs elute with 
the solvent front.
E thanol: water mixtures
The next solvent tried was ethanol. The percentages of ethanol used 
were 5,10,20 and 30% with the results shown in Diagram 19.
Diagram 19 : Enantiomeric resolution of chiral benzodiazepines versus
percentage ethanol
resolution
temazepam4 --
oxazepam
lormetazepam
5 10 20
% ethanol
Again from the results it can be seen that 10% solvent gives the best 
separation of enantiomers for temazepam and oxazepam. The enantiomers
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of lormetazepam were again poorly resolved with one peak only at 2 0% 
ethanol. At 30% ethanol all drugs eluted with the solvent front.
Propan-1-ol: water mixtures
Propan-l-ol: water mixtures attempted here were 5,10 and 20% 
organic solvent with the results shown in Diagram 20.
Diagram 20 : Enantiomeric resolution of chiral benzodiazepines versus
percentage propan-l-ol
r e s o l u t i o n
5
0 -I---------- 1 1----1------ 1------- 1-------1 1-------1--------1------1
5 6 7 8 9 10
% propan-l-ol
Here it can be seen that 5% propan-l-ol is the optimum amount of 
solvent required for temazepam and oxazepam, with lormetazepam giving a 
poor enantiomer separation at 5% propan-l-ol and one peak at 10% propan-
l-ol. It should be noted that as the percentage of propan-l-ol is decreased
chromatographic peaks broadened and capacity factors increase to a level 
unrealistic for analysis (k' >16).
t e m a z e p a m
o x a z e p a m
l o r m e t a z e p a m
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Acetonitrile: water mixtures
As with propan-l-ol, the percentages of acetonitrile tried were 5,10 
and 20%. The results are shown in table and Diagram 21.
Diagram 21: Enantiomeric resolution of chiral benzodiazepines versus
percentage acetonitrile
resolution
3
2.5
2
1.5
1
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0
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temazepam
oxazepam
lormetazepam
% acetonitrile
The results here are similar to propan-l-ol in that 5% solvent gives the 
optimum resolution of the drugs in the range evaluated.
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The data outlined above can be plotted per drug, so that solvent 
effects are more apparent. Lorazepam was not plotted as no enantiomeric 
separations were observed on any of the mobile phases attempted. The 
combined results are shown in Diagrams 22-24.
Diagram 22 : Enantiomeric resolution of temazepam versus percentage
solvent
resolution
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3
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1
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propan-l-ol
acetonitrile
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Diagram 23 : Enantiomeric resolution of oxazepam versus percentage solvent
resolution
10
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Diagram 24 : Enantiomeric resolution of lormetazepam versus percentage
solvent
resolution
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As can be seen in diagrams 22-24, the resolution of each drug was at 
an optim um  value at a certain solvent concentration. For temazepam and 
oxazepam, the optimum amount of solvent was 10% for methanol and 
ethanol and 5% for acetonitrile and propan-l-ol. However any one of the 
mobile phases tried for oxazepam gave an acceptable enantiomeric 
resolution.
Lormetazepam and lorazepam chromatographed poorly on the 
aqueous : solvent systems. One explanation is that because these two drug 
molecules each have two chlorinated benzene rings which have a high 
affinity for the cyclodextrin, cavity and both may form a complex. If this is 
the case then the drug molecules will not form a complex in one particular 
way and so total resolution cannot occur. It may, however, be possible to 
separate the enantiomers of these 2  in the polar organic mode where 
hydrogen bonding would replace inclusion complexation.
One of the main problems which was noticed on all mobile phases 
was peak tailing and it was decided to substitute for water w ith phosphate 
buffer.
11.2.1.6 Effects of phosphate buffer
As suggested above, phosphate buffer replaced water in the mobile 
phase system. Also the mobile phase optimisation studies concentrated on 
temazepam and oxazepam, with no further work being done on 
lormetazepam or lorazepam.
A mobile phase tried was 10% methanol in 0.05M phosphate buffer 
(pH 6 .8 ). The results are shown below in Table 19.
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Table 19 : Comparison of enantiomeric resolution of temazepam and
oxazepam between 1 0% methanol in water and buffer
mobile phase resolution
temazepam
resolution
oxazepam
M eO H : buffer 
10:90
2.28 6.07
M eO H : water 
10:90
3.52 8.96
When the results are compared to 10% methanol in water it was found 
that peak shapes improved with less tailing noticed. However the resolution 
dropped from 3.52 to 2.28 and 8.96 to 6.07 for temazepam and oxazepam 
respectively and these results were more comparable to 2 0 % methanol in 
water.
If 10% methanol in buffer (pH 6 .8 ) gave similar enantiomeric resolutions to 
20% methanol in water, then it may follow that 2.5% acetonitrile in buffer 
(pH 6 .8 ) m ay be similar to 5% acetonitrile in water (since 5% was the 
optimum acetonitrile concentration in water). Improved enantiomeric 
resolutions were noted in the 2.5% acetonitrile in buffer (pH 6 .8 ). However 
long retention times and broad peaks were noted and so 5% acetonitrile in 
buffer was tried. This mobile phase was tried with 3 different pH 's and the 
results shown below in Diagram 25 .
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Diagram 25 : Enantiomeric resolution of temazepam and oxazepam versus
pH
resolution
6 - -
4 -■
83 5 6 74
temazepam
pH
From this 5% acetonitrile in buffer (pH 6 .8 ) was selected as a possible 
mobile phase for two reasons. The first was that when biological extracts 
(originating from spiked whole blood) were used less interferences were 
noted from the biological matrix. The second reason is that 5% acetonitrile in 
buffer has acceptable capacity factor values for the analyst (k' 2.89 for 
temazepam enantiomer 1 and 4.37 for temazepam enantiomer 2)
As can be seen from Diagram 24 a near linear relationship exists between 
enantiomeric resolution, which increases with pH.
A pH  of 7.35 was selected for the buffer. This pH  gave a good 
enantiomeric resolution of both analytes and also fell within the pH  range of 
the column (pH 3.0-7.5).
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Chapter 12 : Results and discussion II
12.1 Introduction
The enantiomers of 3-substituted-l,4-benzodiazepin-2-ones have 
different binding constants to hum an and animal proteins and tissues and 
the binding to hum an serum albumin and bovine and rat cerebral cortex was 
discussed in section 8.4.
After evaluating the P-cyclodextrin stationary phase for separations of 
3-hydroxy-l,4-benzodiazepin-2-ones from solution, it was evaluated as a 
separation technique for toxicological purposes. A pharmacokinetic study of 
temazepam enantiomers in serum samples from a human volunteer was 
designated as a suitable evaluation as a preliminary to the analysis of post­
mortem blood samples.
After the evaluation for toxicological purposes a semi-preparative 
chiral chromatographic separation of temazepam enantiomers was carried 
out and the isomers were individually analysed by circular dichroism 
analysis.
12.2 Extraction
Whole blood was spiked with temazepam, oxazepam, and diazepam 
(internal standard) and two solid phase extraction methods were tested.
The first method was based on the routine extraction procedure used in the 
Department of Forensic Medicine and Science using Extrelut® and the 
second was solid phase extraction solid phase extraction using octylsilica
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stationary phase. In addition a liquid-liquid extraction technique was carried 
out on samples obtained from semi-preparative chiral chromatography.
12.2.1 Extrelut® extraction
The Extrelut® extraction will not be discussed further as extracts were 
extremely messy with quantification of the drugs impossible on the P- 
cyclodextrin stationary phase.
12.2.2 Solid phase extraction on octylsilica
Blank whole blood and blank serum were extracted by a non-polar 
solid phase extraction method on octylsilica. The recovery of each 
benzodiazepine is summarised in Table 20.
Table 20 : SPE extraction of three benzodiazepines from blood and serum
compound % recovery from blood % recovery from serum
oxazepam 65 68
temazepam 62 63
diazepam 59 62
As Table 18 shows, the % recovery of all three drugs is greater from 
serum samples than whole blood. This seems reasonable because whole 
blood is a more complex mixture than serum, and it is generally more 
difficult to quantify drugs from this matrix. The recoveries are relatively low 
compared to many solid phase extraction methods and the method could be 
improved for achiral chromatographic methods. As the method in section
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1 0 . shows, acidic or basic conditions are avoided in the extraction to exclude 
the possibility of racemisation.
12.2.3 Liquid-liquid extraction for semi-preparative samples
Four solvents were evaluated for the liquid-liquid extraction of 
racemic temazepam in water. The results are shown below in Table 21.
Table 21: Liquid-liquid extraction of temazepam from water
solvent % recovery
ethyl acetate 65
diethyl ether 61
dichloromethane 55
chloroform 60
As the above table shows, the four solvents extract a similar amount of 
temazepam from the water. Diethyl ether was chosen as the solvent of 
choice due to its low volatility and thus ease of removal.
12.3 Chromatography
12.3.1 Chiral
The chiral chromatographic system consisted of a P-cyclodextrin 
column with a mobile phase of 5% acetonitrile in 0.05M phosphate buffer
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(pH 7.35). UV detection was at 254nm and the mobile phase flow rate was 
0 .8m l/m in. The capacity factors are shown in Table 22.
Table 22 : Capacity factors of temazepam enantiomers and diazepam
benzodiazepine k'
temazepam enantiomer 1 2.89
temazepam enantiomer 2 4.37
diazepam 5.63
A typical chromatogram is shown in Diagram 26.
Diagram 26 : Chromatogram of temazepam enantiomers and diazepam
temazepam 
enantiomer 1 temazepam enantiomer 2
diazepam
start
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12.3.2 Achiral
The method used for the non-chiral analysis is outlined in section 10., 
and is from the UN benzodiazepine manual [154]. The methods is 
recommended for dissolved tablet samples, but worked well here with 
samples derived from serum.
The capacity factors for the three benzodiazepines analysed are shown below 
in Table 23.
Table 23 : Capacity factors of three benzodiazepines on C18 stationary phase
benzodiazepine k'
oxazepam 4.75
temazepam 5.75
diazepam 9.55
12.3.3 Semi-preparative chiral separation
A semi-preparative chiral separation of racemic temazepam was carried out 
so that larger quantities of each enantiomer could be collected. Twenty 
separate injections of racemic temazepam were performed w ith 24 |ig loaded 
on column each time.
UV spectrometry was then employed to quantitate each enantiomer. The 
quantity of enantiomer 1 (first eluting enantiomer) was 54 jig and the 
quantity of enantiomer 2 was 50 jig, with both being quantified at 232nm. 
The UV spectra of each along with that of racemic temazepam standards is 
shown below in Diagrams 27-29.
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Diagrams 27-29 shown that there is a slight difference in the three UV 
spectra. The UV spectra of the two enantiomers are more similar to each 
other than the racemic temazepam spectra. However the UV spectra of the 
enantiomers have several shoulder peaks on the main absorbance at Amax. of 
244nm for enantiomer 1 and 240nm for enantiomer 2. When the two UV 
spectra of each enantiomer are compared to that of the racemate in this way 
it suggests there are impurities present.
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12.4 Circular dichroism spectrum
The circular dichroism spectrum of each enantiomer and that of the 
solvent, ethanol, is shown in Diagram 30. As the diagram shows both 
enantiomers and the solvent blank have the same spectral characteristics of 
no CD absorbance. This may be due to the samples being impure (as 
suggested by the UV spectra), racemisation of the enantiomers has occurred 
or the quantity of each enantiomer (approximately 50 |xg) is too small.
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Diagram 30 : Circular dichroism spectra of temazepam enantiomers
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12.5 Pharmacokinetic studies
As mentioned in the introduction to this chapter, a healthy male 
volunteer completed two separate pharmacokinetic studies with temazepam, 
involving oral doses of 10 and 20 milligrammes racemic temazepam. The 
results from both pharmacokinetic studies are shown below in Diagrams 31 
and 32
Diagram 31: Plasma concentration curves of temazepam enantiomers
following a 10 mg oral dose
conc. (ng/ml)
3 0 0
enantiomer 1
2 5 0
enantiomer 2
200
total drug
1 50
100
5 0
0
2 55 15 200 10
time (hours)
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Diagram 32 : Plasma concentration curves of temazepam enantiomers
following a 20  mg oral dose
conc. (ng/ml
1 4 0
enantiomer 1120
enantiomer 2
100
total drug
5 0 6 04 010 20 3 0
time (hours)
It can be seen from Diagram 31 that the ratio of enantiomers is 
approximately one until 12-13 hours. After this the ratio changed slowly 
until 23 hours as the concentration of the second enantiomer decreased more 
quickly than the first enantiomer. A similar situation was noted with the 20 
milligramme oral dose (shown in Diagram 32) and continued up  to 60 hours. 
Oxazepam, the main metabolite of temazepam (ignoring glucuronides) was 
not seen in any of the samples. This suggests that the differences in 
concentration between the two temazepam enantiomers is due to 
stereoselective binding rather than stereoselective metabolism, although it is 
certainly possible that both could occur. It is still unclear from the study the 
fate of the temazepam after entering the body. One partial solution to this
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problem is to extend the method to measure temazepam and oxazepam 
glucuronides in plasma, and also collect samples of urine for similar analysis.
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Chapter 13 : Conclusions and suggestions for further work
13.1 Nifedipine analysis
This study involved finding a suitable and robust method for the 
analysis of nifedipine and its metabolites from whole blood. The extraction 
methods evaluated were liquid-liquid extraction, solid phase extraction and 
protein precipitation plus solid phase extraction.
It was concluded that the liquid-liquid extraction was unsuitable for 
the purposes because of many co-extracted interferences. Solid phase 
extraction was better because recoveries of drug material were high. 
However problems persisted because whole blood blocked one-third of all 
columns used. The method of choice was protein precipitation plus solid 
phase extraction because blood extracts were free of significant interferences. 
The method had a relatively low recovery of 48% for nifedipine but blockage 
of solid phase extraction columns did not occur.
13.2 Evaluation of (3-cyclodextrin stationary phase for chiral 
chromatography of four common benzodiazepines
Evaluation of four benzodiazepines (temazepam, oxazepam, 
lorazepam, lormetazepam) was carried out using a (3-cyclodextrin column, 
with several solvent combinations.
When using a (3-cyclodextrin column under reversed phase conditions 
it could be concluded that the enantiomers of lorazepam and lormetazepam 
will not be resolved on this stationary phase, whereas the enantiomers of
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temazepam and oxazepam would separate well under these conditions. 
Other conclusions are that a decrease in organic modifier concentration (in 
water or buffer) increased the enantiomeric resolution but also increased the 
retention, and that increasing the pH  increases the enantiomeric resolution 
for temazepam and oxazepam.
13.3 Pharmacokinetic study
Two pharmacokinetic studies were carried out on temazepam 
enantiomers. Two separate doses of temazepam, 10 and 20 mg, were given 
to a healthy male volunteer and samples taken over 23 and 60 hours 
respectively.
It was concluded that the enantiomers were treated similarly in 
binding a n d /o r metabolism until 12 or 13 hours as the enantiomeric ratio is 
1:1 up to this point. After this time the concentration of the first eluting 
enantiomer fell more slowly than the second which suggests a process such 
as stereoselective binding or metabolism.
In the studies no trace of the temazepam metabolite, oxazepam, was 
noted which suggested this metabolite is not formed in blood. However the 
method is not sensitive for glucuronides and thus no conclusions about these 
metabolites could be made.
It could also be concluded that direct chiral chromatographic analysis 
is possible for toxicology but difficulties still exist due to the fragility of the (3- 
cyclodextrin stationary phase toward extracted samples of biological origin.
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13.4 Further work
Further work could (a) include a investigation of p-cyclodextrin 
columns from a different manufacturer to check if all p-cyclodextrin phases 
are fragile towards extracted biological samples, (b) applying the method to 
post-mortem blood samples, and (c) extending the study to analyse 
temazepam and oxazepam glucuronides in blood or urine. Since the 
glucuronides are diastereoisomers they could also be analysed by achiral 
chromatography.
Also, other methods of chiral analysis such as chiral derivatisation (to 
form diastereoisomers) for gas chromatography or high performance liquid 
chromatography could be evaluated as these may be more robust towards 
extracted biological samples. Mobile phase additives for capillary 
electrophoresis may be considered, as low sample volumes and small 
quantities of reagents are required. All of these analytical techniques could 
be applied to other optically active drugs of forensic interest such as the ring 
substituted amphetamine derivative 3,4-methylenedioxymethamphetamine 
(MDMA).
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Appendices
A. Analysis of Nifedipine in Whole Blood Samples
Calum M. Morrison* and Robert A. Anderson, Department of Forensic 
Medicine and Science, University of Glasgow, Glasgow G12 8QQ, UK
Abstract
Nifedipine is an anti-anginal/anti-hypertensive drug which acts as a 
slow calcium channel blocker. It is widely used in the UK and occurs 
regularly in medicolegal cases requiring toxicological analysis. Careful 
sample handling and analysis is required, particularly the exclusion of light. 
Isolation involves solid phase extraction on octylsilica following 
deproteination with methanol. Other non-polar phases were evaluated 
(octadecylsilica, ethylsilica, phenylsilica and cyclohexylsilica). Analysis by 
HPLC utilised a ODS column and UV detection at 238nm. The limit of 
detection was 5ng/m l blood, and the method was evaluated using case 
samples of autopsy blood.
Keywords: Nifedipine, whole blood, SPE/HPLC, overdose 
Introduction
Nifedipine is the prototype drug of the group of dihydropyridine 
calcium-channel blocking agents, also known as calcium antagonists, calcium 
entry blockers or slow calcium blockers. The drug inhibits the influx of
157
calcium ions into muscle cells and also binds to the intracellular calcium 
binding proteins. It has a selective effect as a dilator of arterial vessels. This 
causes dilation of the pulmonary, coronary and peripheral arteries resulting 
in a fall in blood pressure. The drug is used for the treatment of 
hypertension and angina pectoris.
The aim of this study was to find the best commercially-available non­
polar sorbent for solid phase extraction (SPE) of nifedipine from blood. The 
only polar material tested was Extrelut®. The majority of papers published 
for the analysis of nifedipine from blood, plasma, serum or urine involve 
liquid-liquid extraction. A wide range of solvents has been used for 
nifedipine extractions and these are highlighted in a recent review paper [1]. 
Approximately five methods using solid phase extraction have been 
published to date. Two of these methods involve on-line pre-column 
extraction [2,3] while another combines SPE on octadecylsilica (ODS) and 
basic solvent extraction [4]. Extractions from fetal calf serum using octylsilica 
[5] and from human serum using ODS [6 ] have also been published.
Absorption of nifedipine from the gastro-intestinal tract is rapid and 
almost complete, although bioavaliability after oral administration is 
between 45 and 75% [7]. Following administration by mouth, peak blood 
concentrations are reported to occur 30-120 minutes after consumption, with 
a plasma half life of 2-5 hours[8 ].
The metabolism of nifedipine takes place almost exclusively in the liver, 
where it is converted into three pharmacologically inactive metabolites 
which are excreted in the urine (80%) and faeces (20%). A scheme for this 
metabolism is outlined in Figure 1 and involves oxidative dehydrogenation 
to dehydronifedipine (BAY B 4759, structure 2), followed by demethylation 
to the pyridine mono-carboxylic acid metabolite (BAY O 2820, structure 3), 
then oxidation of the 2-methyl group to the primary alcohol (BAY H 2228,
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structure 4). This metabolite undergoes pH-dependent cyclisation to the 
lactone (BAY O 4160, structure 5) [9].
Overdose levels of nifedipine have not been reported in the literature, 
as far as we know, but several publications on nifedipine poisoning from a 
medical angle have been published [10-15].
159
DIAGRAM 1 - METABOLISM OF NIFEDIPINE
NO,
CH
CH
Structure! - Nifedipine
no2
COoCH
CH
Structure2 - BAY B 4759
h 3c o 2c
Structure5-BAY 04160
CH CHoOH
Structure3 - BAY 0  2820 Structure4 - BAY H 2228
160
Experimental
Materials:
All sample handling and extraction steps were carried out with 
glassware w rapped in aluminium foil to prevent degradation of nifedipine 
by light. Dichloromethane, methanol, butan-l-ol, chloroform, acetonitrile 
and propan-2-ol were of HPLC grade and supplied by BDH. Hexane and 
pentane were purchased from Aldrich (UK). Cetrimide (hexadecyl- 
trimethylammonium bromide) was obtained from Sigma UK Ltd. C18 
(octadecyl), C8  (octyl), C2 (ethyl), CH (cyclohexyl) and PH (phenyl) Bond- 
Elut solid phase extraction columns were supplied by Varian, and Extrelut® 
granules were obtained from Merck.
Reference standards of nifedipine, nitrendipine and metabolites were 
kindly donated by Bayer (Germany) Ltd. Specimens of autopsy blood were 
obtained at routine post-mortem examinations in the Glasgow area.
Standard solutions were prepared in bottles covered with aluminium 
foil and dissolved in methanol. Two stock solutions were prepared and had 
the following composition-
Stock solution 1: nifedipine 6.1 pg /m l, bay-b-4759 3.6 pg /m l, bay-o-4160 
5.8pg/ml and bay-h-2228 7.1 pg /m l. Stock solution 2: nitrendipine 7.9 
pg/m l.
Instruments:
The HPLC system consisted of a solvent pum p (LDC/Milton Roy 
Constametric®3000), external injection valve with a 2 0pl loop, column
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(250x4.6 mm i.d., ODS HL5), UV detector (Waters 490-MS) at 238nm and a 
recorder (Linseis NRE-6 8 ). The mobile phase consisted of water:acetonitrile 
50:50 w ith 20mM cetrimide and was used at a flow rate of 1.0 m l/m in. The 
pH  of the mobile phase was 7.9.
Extraction procedures:
Several methods for the extraction of nifedipine from blood were 
evaluated. These included solvent extraction (A), direct loading of blood on a 
solid phase material (B) and protein precipitation or Extralut®
(diatomaceous earth) extraction as an initial stage before solid phase 
extraction using modified silicas (C).
A. Solvent extraction with methanol, chloroform, ethyl acetate or diethyl 
ether:
0.9ml of spiked blood containing lOOpl of stock solution 1 and lOOpl of 
stock solution 2  was added to 10ml of the solvent in a dropwise manner.
After centrifugation (2400rpm, 15 minutes), separation and evaporation of 
the organic layer the extract was reconstituted in methanol and analysed by 
HPLC.
B. Direct loading of blood on a solid phase material:
The materials tested were Extrelut® and Bond-Elut C18, C8 , C2, CH 
and PH.
For Extrelut® extraction a 5ml syringe was filled to the 3ml level (approx.
0.7-0.75g) with Extrelut® granules. 1ml of blood containing lOOpl of stock 
solution 1 and 100pl of stock solution 2  was then added and allowed to 
absorb for 5 minutes. The elution step involved passing of 10 ml of methanol
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or chloroform through the cartridge followed by evaporation of the solvent 
and reconstitution in methanol.
For the Bond-Elut C18, C8 , C2, CH and PH solid phases the following 
procedure was used-
1 . Conditioning-1 column volume of methanol
- 1 column volume of water
2. Application of sample-the sample was allowed to flow 
through the column very slowly, over 3-5 minutes
3. Rinsing - 1 column volume of water
- 1  column volume of hexane 
- 1  column volume of pentane
4. Elution - 2 column volumes of eluting solvent.
The solvent was evaporated and the extract reconstituted in methanol. 
Eluting solvents tried were dichloromethane, chloroform, 5% v /v  butan-l-ol 
in dichloromethane and 10% v /v  butan-l-ol in dichloromethane.
C. Combination of protein precipitation/Extrelut® with solid phase 
extraction
Protein precipitation: 1ml of blood containing lOOpl of stock solution 1 
and lOOpl of stock solution 2 was added drop wise to 5ml of methanol and 
mixed for 15 minutes. After centrifugation (2400rpm, 15 minutes), separation 
and evaporation of the methanol, the extract was reconstituted in 1ml water 
and applied to a Bond-Elut PH solid phase extraction column.
Extrelut®: 1ml of spiked blood was added to Extrelut® as in (B). 
Elution was tried with 10 ml of chloroform, 20% methanol in chloroform and 
40% methanol in chloroform. After the solvent had been evaporated the
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extract was reconstituted in 1ml water and applied to a Bond-Elut C8 solid 
phase extraction column.
Procedure for Bond-Elut PH and C8 extraction :
1. Conditioning - 1 column volume of Methanol
- 1  column volume of water
2. Application of sample - the sample was allowed to flow 
through the column very slowly over 3-5 minutes
3. Rinsing -1 column volume of water
- 1 column volume of hexane 
- 1  column volume of pentane
4. Elution - 2 column volumes of 10% butan-l-ol in 
dichloromethane.
The solvent was evaporated and the extract was reconstituted in methanol.
Results and discussion
Under the HPLC conditions described the following retention times 
were noted : BAY H 2228-4.4 minutes, BAY B 4759-5.4 minutes, Nifedipine- 
6.5 minutes, Nitrendipine-10.0 minutes and BAY O 4160-16.5 minutes.
Each of the extraction procedures which were evaluated worked to a 
certain extent except for solvent extraction.
A. Solvent extraction:
Regardless of the solvent used (4 were tried) too many interferences 
were co-extracted from the blood to allow drug or metabolite peak 
identification and quantification. Back-extraction was not attempted as 
Nifedipine and internal standard Nitrendipine have no ionisable groups
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which could be used without structural alteration of the dihydropyridine 
ring.
B. Direct loading of blood on substituted silica sorbents :
This was evaluated extensively. The first column tested was the least 
selective non-polar material Bond Elut C18, with phosphate buffer at pH  5.2, 
7.3 and 10.3 used to condition the columns instead of water. The results are 
shown in Table 1.
TABLE 1. Bond-Elut C18 Column Elution with Dichloromethane : Effect of 
pH  during conditioning
COMPOUND % RECOVERY
pH 5.2 pH 7.3 pH 10.3
BAY H 2228 / / /
BAY B 4759 66 57 49
NIFEDIPINE 37 34 46
NITRENDIPINE 40 38 35
BAY O 4160 / / /
Examination of the results shows that the pH of the buffer used to 
condition the sorbent does not affect the percentage recovery of the drug or 
its internal standard. However, only one of the metabolites was eluted, 
prompting an evaluation of chloroform as an eluting solvent due to its 
greater polarity. This eluant was not used subsequently due to interference 
caused by co-extracted compounds. The eluting solvent was changed to 5%
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butan-l-ol in dichloromethane with Bond Elut C18 and C8  sorbents being 
used. The results are shown in Table 2.
TABLE 2: Elution with 5% Butan-l-ol in Dichloromethane
COMPOUND % RECOVERY
C18 C8
BAY H  2228 / 8.6
BAY B 4759 102 62
NIFEDIPINE 81 61
NITRENDIPINE 53 47
BAY O 4160 / 30
The percentage recovery of Nifedipine, Nitrendipine and BAY B 4759 
from the C18 column was improved, although the C8 material did extract all 
of the substances from the blood. Further evaluation was carried out of C8 
and the more selective sorbents Bond Elut C2, CH and PH using 10% butan- 
l-ol in dichloromethane as eluant. The results are shown in Table 3.
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TABLE 3: Elution w ith 10% Butan-l-ol in Dichloromethane
COMPOUND % RECOVERY
C8 C2 CH PH
BAY H 2228 22 23 19 13
BAY B 4759 77 68 95 96
NIFEDIPINE 61 44 85 93
NITRENDIPINE 49 60 95 61
BAY 04160 25 / 16 /
An increased recovery from the C8  sorbent was observed and high 
recoveries of nifedipine, nitrendipine and the main metabolite BAY B 4759 
were obtained from the other sorbents. From these results either C8 , C2, CH 
or PH sorbents combined with eluting solvent of 10 % butan-l-ol in 
dichloromethane are suitable for nifedipine extraction from whole blood. 
When the percentage of butan-l-ol was increased further (to 20% by volume) 
significant co-extracted interferences were noted. However, a major 
disadvantage of this method was that approximately 1 in 3 solid phase 
extraction columns became blocked by the blood.
The only polar sorbent tried in these studies was Extrelut® 
(diatomaceous earth). Elution with methanol was found to result in many 
interfering peaks while chloroform elution gave poor recoveries, as shown in 
Table 4.
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TABLE 4: Elution with Chloroform from Extrelut®
COMPOUND % RECOVERY
BAY H 2228 /
BAY B 4759 34
NIFEDIPINE 15
NITRENDIPINE 14
BAY 04160 /
Although recoveries from direct loading of blood on non-polar 
sorbents were good in some cases, the method had to be modified to allow 
the sample to flow through the column more easily without blockage.
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C. Combination of protein precipitation/Extrelut® with solid phase
extraction:
To overcome the viscosity problem an initial step of either Extrelut® 
or protein precipitation was tried. With Extrelut®, 3 eluants were tried 
followed by a second stage of solid phase extraction on Bond Elut PH 
sorbent. The results are shown in Table 5.
TABLE 5: Extrelut® and Bond Elut PH Solid Phase Extraction
COMPOUND % RECOVERY
% METHANOL IN 
CHLOROFORM
0 20 40
BAY H 2228 19 43 10
BAY B 4759 30 103 21
NIFEDIPINE 23 37 9
NITRENDIPINE 14 45 15
BAY O 4160 / 6 8
The results suggest that 20% methanol in chloroform is the optimum 
eluting solvent. A calibration curve was prepared using this method, 
although some decomposition of Nifedipine to BAY B 4759 occurred. This 
may have been due to the quantity of solvent required for removal by 
evaporation (10 ml from Extrelut® + 5 ml from PH elution). This suggests 
the method is unsuitable as many methods in the literature caused no 
significant degradation.
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A combination of protein precipitation in methanol combined with 
solid phase extraction using Bond Elut C8 was subsequently used to 
construct a calibration curve.
Calibration curve for Nifedipine
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The calibration curve for Nifedipine was linear over a range of 
concentrations from 6.1-244ng/ml. The correlation coefficient was 0.991.
Toxicology Cases
In 1994 our Department received 3 fatal toxicology cases in which 
analysis of nifedipine was requested. Autopsy blood was analysed using the 
method described for the preparation of the calibration curve. Two of the 
cases were found to be positive.
The first case was found to be positive for nifedipine (8.3 pg/m l) and 
metabolite Bay-H-2228 (0.5 |ig/m l). The second case was found to be
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positive for nifedipine (6.9 pg/m l), plus metabolites Bay-H-2228 (0.43 pg/m l) 
and Bay-B-4579 (2.7 pg/m l).
Conclusion
The work described above suggests that most non-polar methods of 
solid phase extraction are suitable for the extraction of nifedipine. When 
whole blood is used an appropriate protein precipitation step is 
recommended. Although nifedipine is photodegradable, the analysis can be 
carried out using conditions described in this paper quite easily and reliably 
providing a suitable light exclusion method is implemented.
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Pharmacokinetics of Temazepam Enantiomers in Human Serum
C.M Morrison and R.A. Anderson 
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UK
Abstract
Organisations such as the EC and FDA have prepared draft guidelines 
for separate patents on enantiomers of chiral drugs. A recently published 
paper reviews current draft guidelines for Canada, EC, Japan and the United 
States [1].
In this study, a chiral chromatographic method has been developed 
for separation of the enantiomers of temazepam, a widely abused 
prescription drug important to the forensic toxicologist. A brief review of 
chiral pharmacodynamics and chromatography is also presented.
Extraction from human serum involved the use of solid phase 
extraction on octylsilica (C8 ), with direct chromatographic enantiomer 
separation on a P-cyclodextrin stationary phase. Total drug concentrations 
were measured on an ODS stationary phase.
A pilot metabolism study was carried out which consisted of oral 
administration of 2  separate therapeutic doses to a healthy male volunteer. 
The doses were 10 and 20 mg with blood samples collected up to 23 and 60 
hours respectively.
Introduction
Chirality is defined as the property displayed by any object which is 
not superposable (superimposable) on its mirror image. It is an important 
property which many drug molecules possess. Most naturally occurring 
medicinal agents exist in their optically active or single isomer form. 
However, many synthetic chemicals are produced as the optically inactive 
racemate. A survey in 1993 showed that a greater percentage of synthetic 
drugs were being sold as single enantiomers as compared to 1982 [2]. This 
trend may be due to improvements in chiral separations or chiral synthesis 
and tighter regulatory controls.
Since human and animal systems are chiral environments, drug 
enantiomers may have different effects/actions in these systems. Three main 
situations exist when describing the pharmacodynamic effects of 
enantiomers.
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The first of these is when each enantiomer has the same 
pharmacodynamic effect. This is true of temazepam and other 3-substituted
l,4-benzodiazepin-2-ones. In this case different potencies exist, with the (S)- 
enantiomers up to lOOx more potent than the (R). The case of equal potencies 
is very rare an example being the antihistamine promethazine.
The second situation is where all the activity resides in 1 enantiomer 
and the other enantiomer is biologically inactive. An example of this is the 
antihypertensive agent a-methyldopa.
The third situation is when a useful/harm ful pairing exists. Examples 
of this are numerous, perhaps because the harmful effects have attracted 
attention. These include the anaesthetic ketamine where most post operative 
side effects, such as nausea and hallucinations, are associated with the (R)- 
enantiomer. Other examples include the ring substituted amphetamines 
such as MDMA and MDA. In these drugs the S-(+) enantiomers undergo 
demethylation faster than the R-(-) enantiomers. The S-(+) enantiomers are 
more neurotoxic (from metabolite) and pharmacologically more active [3].
Terminology sometimes used in the literature should be noted here. 
Eutomer describes the isomer with the desired activity while the distomer is 
the enantiomer which is inactive or has the unwanted activity.
For enantiomeric separations by chromatography, diastereoisomeric 
complexes must be formed. This is because enantiomers are chemically and 
physically identical, differing only in optical rotation, whereas 
diastereoisomers are different compounds. Diastereoisomeric complexes can 
be formed in three main ways, namely by chiral derivatisation, using chiral 
mobile phase additives or using chiral stationary phases.
Chiral derivatisation involves the use of enantiomerically pure 
derivatising reagents to react w ith the analytes (mixture of enantiomers) to 
form diastereoisomeric complexes. These diastereoisomers, being different 
compounds, can be separated by achiral chromatographic methods, most 
commonly GC but also HPLC and CE.
(R) + (R,S) (R,R) + (S.S)
reagent analyte diastereoisomers - 
different compounds
typical reagents:
COCI
(-)-camphanic acid chloride (S)-(-)-N-(trifluoroacetyl)-
prolyl chloride
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The second method of diastereoisomeric formation is the use of chiral 
mobile phase additives. Here optically pure molecules such as cyclodextrins 
or transition metal amino acid complexes are added to the mobile phase w ith 
an achiral stationary phase being used. This method is used in HPLC and CE 
analysis.
The third method of chiral analysis involves the use of chiral 
stationary phases. Many phases have been developed and are available 
commercially, and are grouped according to their interactions. The classes 
for HPLC are listed below :
Type I : Pirkle phase
Type I I : Celluloses
Type H I: Inclusion complexes - cyclodextrins, crown ethers
Type IV : Ligand exchange phases
Type V : Bound proteins - HSA, BSA, AGP, OVM
New phase : macrocyclic antibiotics
The phases for GC are mainly based on cyclodextrins, but a few others 
include hydrogen bonding phases and metal coordination compounds.
The HPLC stationary phase used in this study was a native P- 
cyclodextrin stationary phase as show below :
OH
OH
OH
O OH
O — C — N — S i - O — SiOH
HO
si l ica
OH
HO
OH
The separation is based on the formation of inclusion complexes, as 
represented b e low :
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Experimental 
M aterials:
Acetonitrile and methanol were of HPLC grade and were supplied by BDH. 
Hexane was supplied by Aldrich (UK). Potassium dihydrogen 
orthophosphate was of AnalaR® grade and supplied by BDH. Sodium 
hydroxide was GPR grade and supplied by BDH. C8 (octyl) Bond-Elut solid 
phase extraction columns were supplied by Varian, Harbour City, CA, USA.
Chrom atography:
The HPLC columns were as follows :
Chiral analysis - 250 x 4 mm i.d. Chiradex® p-cyclodextrin + guard 
column (Merck);
Achiral analysis - 250 x 4.6 mm i.d. ODS HL5 + guard column (Capital 
HPLC, Broxburn, West Lothian, UK).
UV detector : Waters 490-MS (Millipore UK Ltd/W aters Chromatography 
Division, Harrow, Middlesex).
HPLC pum p : LKB 2150 (LKB-Produkter AB, Box 305, S-161 26 Bromma, 
Sweden)
Integrator : model HP 3396A
Conditions : UV detection was at 254nm
C hiral: mobile phase 5% acetonitrile in 0.05M phosphate buffer (pH 
7.3), flow rate 0.8 m l/m in.
A chiral: mobile phase MeOH:H2O:0.05M phosphate buffer (pH 7.25) 
flow rate 1.5 m l/m in.
Sample collection and storage :
Blood (10ml) was collected in a heparinised vial and mixed gently. 
Plasma was separated immediately by centrifugation at 3000rpm for 10 
minutes and was frozen until analysed.
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Extraction schem e:
1. defrost samples
2. add 1 ml 0.05M phosphate buffer (pH 6.8) and internal standard
(diazepam)
3. mix samples for 10 min.
4. solid phase extraction on C8
conditioning: 1 column vol. MeOH
1 column vol. buffer (as above) 
add sample slowly over 2-3 min. 
column w a sh : 1 column vol. H2O
2 column vols hexane 
elution: 1 column vol. 80% MeOH in H 2O
Specimen chromatograms are shown below :
temazepam 
enantiomer 1 temazepam enantiomer 2
diazepam
start
Chromatogram of 2 hour plasma sample run on p-cyclodextrin column
177
temazepam
diazepam
start
Chromatogram of 2 hour plasma sample run on C18 column
Results and discussion
The results from both pharmacokinetic studies are shown below in 
figures 1 and 2.
enantiomer 1
enantiomer 2200 +
total drug
150 +
100 +
50 +
0 5 10 15 20 25
time (hours)
Figure 1: Plasma concentration curves of temazepam enantiomers in
following a 10 m g oral dose
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enantiomer 1
enantiomer 2 
total drug
10 20 30 40 50 60
time (hours)
Figure 2 : Plasma concentration curves of temazepam enantiomers in
following a 20 mg oral dose
It can be seen from figure 1 that the ratio of enantiomers is approx. 1 
until 12-13 hours. After this the ratio begins to change. This trend is also 
noted in the 20 mg oral dose and continues up to 60 hours. In both cases it is 
the second enantiomer which has the lower concentration.
Oxazepam, the main metabolite of temazepam (ignoring 
glucuronides) was not seen in any of the samples.
Future applications of this method include using the enantiomeric 
ratio to find time after drug administration. It is also our intention to extend 
the method to post-mortem blood samples and find out if a relationship 
exists between time of death and enantiomeric ratio.
Conclusions
The method developed is reliable for measurement of temazepam 
enantiomers in serum or blood. It can also be extended for oxazepam 
enantiomers. Low levels of each enantiomer can be detected with levels 
down to 10 ng/m l.
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